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Pancreatic cancer is the eight most common form of cancer in Europe with 96.000 new cases 
yearly. This incidence closely matches the mortality rate, thus revealing the aggressive behaviour 
of this tumour. Five-year survival after diagnosis is only 5% with a median overall survival of 2-8 
months. For the patients undergoing surgery, the 5 year survival rate increases to 5% to 25%1-4 
with a median survival of 12- 15 months.3, 5 At presentation only 15-20% of the patients have 
a resectable, and thus possibly curative disease, while the majority of the patients already has 
locally advanced (i.e. unresectable) or even metastasized pancreatic cancer. The retroperitoneal 
location of the pancreas plays an important role in the absence of specific complaints. Obstructive 
jaundice, caused by obstruction of the distal common bile duct by tumours located in the 
pancreatic head, is a late symptom. This lack of evident clinical manifestations frequently results 
in a delayed diagnosis and is one of the reasons why pancreatic cancer is usually detected in late 
stages where curation is no longer an option. 
In the pancreatic head a variety of tumours can be found, all with its own biological behaviour. 
Pancreatic ductal adenocarcinoma originating in the pancreatic ducts is the most common and 
most aggressive tumour resulting in the shortest survival. 
Periampullary tumours are also often encountered in the pancreatic head. Several definitions of 
periampullary cancer co-exist.6 Most authors include cancers originating from distal common 
bile duct, ampulla of Vater or duodenum nearby the ampulla. Some also include cancers located 
within 2 cm of the ampulla of Vater. This definition may even include “periampullary” cancers of 
pancreatic ductal origin.
Furthermore cystic lesions such as mucinous cystic neoplasms and intraductal papillary mucinous 
neoplasms (IPMN) occur in the pancreas. Even if malignant degeneration is present in these 
lesions, survival is beneficial compared to ductal adenocarcinomas (5 year survival 24-74%).7 Less 
frequently pancreatic neuroendocrine tumours (PNETs) or metastasis especially from renal cell 
carcinomas could be localised in the pancreatic head. In this thesis we have studied several clinical 
aspects of only patients with pancreatic ductal adenocarcinomas and periampullary tumours and 
performed experimental in vivo studies using human pancreatic cancer cells.
Resectable pancreatic cancer 
Pancreatic and periampullary cancer is considered resectable if there are no metastases, no 
pathological lymph nodes outside the resection area and no encasement of the tumour ito the 
superior mesenteric artery, celiac trunk or hepatic artery. Less than 270º encasement of the 
portal vein and/ or superior mesenteric vein is considered resectable although for these tumours 
several surgeons also use the term “borderline resectable”. In fact, there is no general consensus 
regarding resectability of pancreatic tumours with venous involvement. This often depends on 
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the exact location of the tumour. Tumours located in the uncinate process with ingrowth in the 
distal superior mesenteric vein are in general more difficult to resect than cranial tumours with 
involvement of the portal vein. 
In case of malignancies in the pancreatic tail, ingrowth into the splenic artery does not result in 
unresectability, because a splenectomy can safely be performed. 
Survival
Due to locoregional recurrence and/ or the development of distant metastases median survival, 
even after radical resection, is 12- 15 months3, 5 with a 5-year survival rate ranging from 
5% to 25%.1-4 The majority of the tumours described in these studies are pancreatic ductal 
adenocarcinomas located in the head of the pancreas. Patients with periampullary carcinoma 
have a more favourable outcome, with a median survival after resection of 25- 42 months8, 9 
and a 5-year survival rate of 40% to 70%.10-17 In the Netherlands median survival after radical 
resection is about 15 months for pancreatic cancer and 45 months for periampullary tumours, 
which is similar to studies from other countries6, 8, 18, 19.
Cause for the survival difference between pancreatic head and periampullary tumours is unclear. 
The classical hypothesis is that these tumours are diagnosed in an earlier stage because of their 
anatomical location, leading to early jaundice and clinical manifestation. An additional cause for 
early detection is that they may be discovered at routine endoscopy for example, in patients with 
familiar adenomatous polyposis. For these reasons periampullary tumours may more frequently 
be amenable to surgical resection than their pancreatic counterparts. Another hypothesis is that 
periampullary tumours represent a separate family of tumours with distinct biological behaviour. 
Although histological they appear very similar, periampullary cancers seem to have a different 
biological basis.20, 21 
Factors negatively influencing survival are a positive resection margin, lymph node metastases, 
a larger tumour size, poor differentiation grade, vaso-invasive and perineural growth. 
Although pathological review reports N0 resection according to standard pathological review, 
micrometastases could be found in 53-73% of patients when lymph nodes are examined with 
advanced techniques such as immunohistochemistry or PCR.22, 23 Furthermore in 37-73% of the 
R0 resections, nerve plexus invasion outside the pancreas can be found.24 
Adjuvant chemo(radio)therapy
One of the causes of a poor survival after resection is the development of local progression 
or distant metastases with recurrence rates as high as 90%. Recurrence occurs locoregional in 
50%-80%, peritoneal in 25% and in the liver in 50% of patients.25 This implies that at the 
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time of diagnosis, pancreatic cancer is already a systemic disease and treatment should not 
be confined to surgical resection. To obtain both local and distant control, the first trials on 
adjuvant therapy included both radiotherapy and chemotherapy. The Gastrointestinal Tumour 
Study Group (GITSG) randomised 43 patients between surgery alone or an adjuvant schedule 
including both chemoradiotherapy and chemotherapy. Adjuvant treatment resulted in better 
overall survival (20 vs. 11 months), but the effect could be caused by either chemotherapy or 
chemoradiotherapy. The European Organisation for Research and Treatment of Cancer (EORTC) 
randomised patients between surgery alone or adjuvant chemoradiotherapy but found no benefit 
of either. The European Study group for Pancreatic Cancer (ESPAC) randomised between surgery 
alone, surgery combined with chemotherapy and chemoradiotherapy in a 2x2 factorial design. 
Although chemotherapy resulted in survival benefit, chemoradiotherapy did not. However, in all 
these studies a split course (2 weeks 20 Gray, 2 weeks rest followed by 2 weeks 20 Gray) was 
used, which nowadays is obsolete. Thus, although no significant benefit has yet been established, 
the possible effect of chemoradiotherapy has not been investigated to its full extent. 
Adjuvant chemotherapy on the other hand results in a longer disease free survival as well as in 
a prolonged survival. The ESPAC group treated patients with 5-FU combined with folinic acid 
during 28 weeks resulting in a survival of 20.1 months (15.5 months in patients not receiving 
chemotherapy). The CONKO-001 treated patients with gemcitabine during 6 months resulting 
in 13.4 months median survival (6.9 after surgery alone) and 23.5% disease free survival after 3 
years (8.5% after surgery alone). A recent trial performed by the ESPAC randomising between 
5-FU combined with leucovorin vs. gemcitabine did not result in a prolonged disease free or 
overall survival in either group (23 vs. 23.6 months median overall survival).26-28
Unresectable pancreatic cancer
In the work-up of patients with suspected pancreatic usually a computed tomography (CT) scan is 
performed. Although reliable for pancreatic masses, enlarged lymph nodes and vascular ingrowth, 
especially small (<1cm) peritoneal and liver lesions can be missed. 29 The extend of vascular 
tumour growth determines the resectability of the pancreatic lesion. Unresectable pancreatic 
cancer should be discriminated from metastasized pancreatic cancer by ruling out metastases 
since only in these patient locoregional radiotherapy either combined with chemotherapy might 
be a therapeutic option.
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Locally advanced unresectable cancer is defined in the Netherlands according to Table 1:
SMA Celiac axis CHA SMV-PV
Resectable 
(all four required)
no contact no contact no contact ≤ 90˚ contact
Borderline resectable
(minimally one required)
≤ 90˚ contact ≤ 90˚ contact ≤ 90˚ contact 90˚-270˚ contact,
and no occlusion
Irresectable 
(minimally one required)
contact > 90˚ contact > 90˚ contact > 90˚ contact > 270˚
or occlusion
SMA: superior mesenteric artery
CHA: common hepatic artery
SMV-PV: superior mesenteric vein-portal vein
Chemo(radio)therapy
Since the publication of the Gastro Intestinal Tumour Study Group (GITSG) in 198130, patients 
with locally advanced pancreatic cancer are treated with radiotherapy in combination with 5 
fluorouracil (5-FU). The median survival after 5-fluorouracil (5-FU) based chemoradiotherapy 
treatment in literature varies between 7- 14 months.31-39 In a number of studies 5-FU has been 
replaced by gemcitabine in the treatment of unresectable pancreatic cancer, either alone, in 
combination with radiotherapy or in combination with other drugs. After treatment with 
gemcitabine either with or without concurrent radiotherapy, median survival varies between 10- 
17 months.32, 35, 37, 39-43
One of the causes for these discouraging results might be the pre-treatment staging because 
small metastatic liver or peritoneal lesions remain undetected by CT scanning. 
To prevent local progression, radiotherapy might play a more important role in unresectable 
than in resectable pancreatic cancer. Besides 5-FU and gemcitabine radiosensitizing properties 
of interferon alpha (IFNa) and interferon beta (IFNb) have been demonstrated in several tumours 
in vitro44-49 as well as in vivo.50, 51 In pancreatic cancer cell lines, IFNa has already shown to act 
as radiosensitizer52 and in vivo promising therapy results have been reported combining 5-FU, 
cisplatinum, and radiation therapy with IFNa alone (5-year survival rate of 55%) or followed 
by 2 cycles of gemcitabine (median survival 25 months) in patients with resected pancreatic 
adenocarcinoma.53, 54
In vivo studies showed that approximately 20% of pancreatic cancers express interferon receptors 
and the expression of the interferon receptor was found to correlate with a significant survival 
benefit in patients with resected pancreatic cancer.55
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OUTLINE OF THE THESIS
Intra-arterial chemotherapy is a promising way of administering drugs. Celiac artery infusion 
delivers the drugs not only directly to the liver through the common hepatic artery, but also 
indirectly through the splenic and left gastric artery and subsequent portal vein. One of the 
benefits of intra-arterial admission of chemotherapy is obtaining a higher local dose with tolerable 
toxicity. Two clinical phase II studies with celiac artery infusion (CAI) suggested that regional 
chemotherapy might extend survival in locally advanced non-resectable as well as in resected 
pancreatic cancers. Intra-arterial chemotherapy reduced hepatic progression from 62% to 17% 
and hepatic metastases related death from 33% to 8%. No reduction in local recurrence rates 
was found in these studies.26-28 Therefore we hypothesized that CAI combined with locoregional 
radiotherapy might prolong survival of patients after curative resection of either pancreatic or 
periampullary cancer. In Chapter 2 we discussed the results of a randomised controlled trial 
we performed in order to investigate our hypothesis. As a consequence of the intra-arterial 
chemotherapy, patients in the treatment arm had an indwelling catheter and were obliged to 
stay in bed throughout all six cycles which might affect quality of life. Patients in the surgery 
alone arm on the other hand, were regularly followed up on outpatient basis, but did not suffer 
from regular admissions or toxicity. We addressed the effect of our regime on quality of life in 
all these patients in Chapter 3. In Chapter 4 we further investigated the long term survival of 
patients treated with intra-arterial chemotherapy and radiotherapy or surgery alone, especially 
considering tumour origin.
In Part II we focus on patients with locally advanced/ unresectable pancreatic cancer. Diagnosis 
in these patients can be difficult and multiple modalities are available for obtaining optimal 
staging. Besides criteria for unresectability based on computed tomography (CT) scan, the role of 
a diagnostic laparoscopy in these patients is addressed in Chapter 5. Patients with unresectable 
pancreatic cancer are known to be at risk for small peritoneal and liver metastases, undetectable 
for CT scan and during a diagnostic laparoscopy these lesions can be detected. The quality of the 
CT scan and the presence of a dedicated radiologist in different centres might also influence the 
detection rate. In Chapter 6 a multicenter trial with the Academic Medical Center, Amsterdam 
is described. Patients with unresectable, non-metastasised pancreatic cancer were treated with 
Uracil/Tegafur (UFT) plus leucovorin and celecoxib combined with radiotherapy in a short, intensive 
schedule. The combination of drugs was in part based on promising research and the possibility 
of oral intake (UFT plus leucovorin) and in part on radiosensitising properties of selective inhibition 
of cyclooxygenase-2 by celecoxib and the presence of the COX-2 receptor in pancreatic cancer. 
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In Part III we took research back into the laboratory. Based on the results of the Virginia Mason 
Clinic, the radiosensitising activity of both interferon (IFN) a and b was further investigated. We 
already described the presence of the IFN receptor on both membrane as well as intracellular in 
different cell lines. The aim of the study presented in Chapter 7 was to assess the radiosensitising 
properties of both types of interferon in a colony forming assay. This method was chosen because 
both the apoptotic effects of radiation and IFN as well as the reproductive integrity of tumour 
cells after treatment is of pivotal importance. 
The general discussion (Chapter 8) and summary and conclusions (Chapter 9) are presented in 
Part IV of this thesis. 
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ABSTRACT
Background: Success of surgical treatment for pancreatic and periampullary cancer is often 
limited due to locoregional recurrence and/or the development of distant metastases. 
Objective: The survival benefit of celiac axis infusion (CAI) and radiotherapy (RT) versus 
observation following resection of pancreatic or periampullary cancer was investigated. 
Methods: In a randomized controlled trial, 120 consecutive patients with histopathologically 
proven pancreatic or periampullary cancer received either adjuvant treatment consisting of 
intra-arterial mitoxantrone, 5-FU, leucovorin and cisplatinum in combination with 30x 1.8 Gray 
radiotherapy (group A) or no adjuvant treatment (group B). Groups were stratified for tumor type 
(pancreatic vs. periampullary tumors).
Results: After surgery, 120 patients were randomized (59 patients in the treatment group, 61 
in the observation group). The median follow up was 17 months. No significant overall survival 
benefit was seen (median 19 vs. 18 months resp.). Progressive disease was seen in 86 patients: 
in 37 patients in the CAI/RT group, and in 49 patients in the observation group (log-rank 
p<0.02). Subgroup analysis showed significantly less liver metastases after adjuvant treatment 
in periampullary tumors (log-rank p<0.03) without effect on local recurrence. Nonetheless, there 
was no significant effect on overall survival in these patients (log-rank p=0.15). In patients with 
pancreatic cancer, CAI/RT had no significant effect on local recurrence (log-rank p=0.12) neither 
on the development of liver metastases (log-rank p=0.76) and consequently, no effect on overall 
survival. 
Conclusion: This adjuvant treatment schedule results in a prolonged time to progression. For 
periampullary tumors, CAI/RT induced a significant reduction in the in the development of liver 
metastases, with a possible effect on overall survival. Especially in these tumors, CAI/RT might 
prove beneficial in larger groups and further research is warranted.
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INTRODUCTION
Pancreatic cancer is one of today’s most fatal malignant diseases and ranks fourth in cancer related 
mortality world-wide.1 Curative surgery is only possible in case of early detection of pancreatic 
cancer, but most patients present with advanced, and thus incurable disease. Resection by partial 
or total pancreaticoduodenectomy is possible in only 5% - 25% of patients. The success of 
surgical treatment is often limited due to locoregional recurrence and/ or the development of 
distant metastases. Even after radical resection, median survival time is 12 - 15 months2, 3 with a 
5-year survival rate ranging from 5% to 25%.2, 4-6 Patients with periampullary carcinoma have a 
more favorable outcome, with a 5-year survival rate of 40% to 70%.7-14
To improve this dismal course after resection of pancreatic cancer, adjuvant treatment has 
been studied in several clinical trials. First, the Gastrointestinal Tumor Study Group (GITSG) 
randomly assigned 43 patients to surgery alone or chemoradiation followed by maintenance 
chemotherapy.15, 16 The median survival was significantly longer in the adjuvant treatment group 
compared with the surgery group (20 months vs. 11 months), with respectively 18% and 8% 
survival at 5 years.15-18 However, this was a small study, which was terminated early because of 
poor accrual. Furthermore, it is unclear whether the survival advantage in the GITSG trial was 
due to the combination of chemoradiation and maintenance chemotherapy or caused by only 
one of these modalities.19 The first large multicenter trial in pancreatic cancer was a randomized 
phase III trial conducted by the EORTC Gastro-intestinal group, initiated in 1987 (EORTC 40891). 
Based on 218 patients, this trial did not show a benefit for adjuvant chemoradiation although 
they suggested a trend in favor of chemoradiation (p = 0.09) in patients with ductal pancreatic 
adenocarcinoma. However, this trial included patients with pancreatic as well as more favorable 
periampullary tumors, 20% of the patients randomized for chemoradiotherapy never started 
therapy and no maintenance chemotherapy was given which could possibly explain the poor 
results.20 Recently Smeenk et al. reported the long-term follow-up results of EORTC trial 40891, 
which assessed the role of chemoradiation in resectable pancreatic cancer. The results confirmed 
the previous short-term analysis indicating no benefit, neither on progression-free, nor on overall 
survival, of adjuvant chemoradiation over observation in patients with resected pancreatic or 
periampullary cancer.21 In 1994, the European Study Group for Pancreatic Cancer (ESPAC) 
undertook a multicenter factorial phase III trial to investigate the possible benefits of adjuvant 
chemoradiation and maintenance chemotherapy in patients with pancreatic cancer. In this trial, 
a deleterious effect of adjuvant chemoradiation on survival was shown, whereas chemotherapy 
significantly improved survival in patients with resected pancreatic cancer.2, 22, 23 However, concerns 
about trial design and the background therapy effect remain overt.24, 25
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Two clinical phase II studies with celiac artery infusion (CAI) suggested that regional chemotherapy 
might extend survival in locally advanced nonresectable as well as in resected pancreatic cancers. 
Celiac artery infusion delivers the drugs not only directly to the liver through the common hepatic 
artery, but also indirectly through the splenic and left gastric artery and subsequent portal vein. 
One of the benefits of intra-arterial admission of chemotherapy is obtaining a higher local dose 
with tolerable toxicity. This treatment reduced hepatic progression from 62% to 17% and hepatic 
metastases related death from 33% to 8%. No reduction in local recurrence rates was found in 
these studies.26-28 
To reduce local relapse, full dose radiotherapy together with sensitizing chemotherapy was given 
by Blackstock with promising results. Patients with resected adenocarcinoma of the pancreas were 
treated with intravenous gemcitabine administered concurrent with upper abdominal radiation 
followed by gemcitabine in case of no progression. Only 18% of the patients with progression 
experienced local regional relapse as a component of the first site of failure. 29 
In the present study we investigated whether we could improve survival of resected patients with 
periampullary and pancreatic cancers by postoperative celiac artery infusion + radiotherapy as 
adjuvant treatment compared to surgery alone. 
METHODS
Study Design and Patients
After resection for cancer of the pancreas or the periampullary (distal common bile duct or 
papilla of Vater) region, patients were randomized and stratified for tumor localization (pancreas 
versus periampullary) to receive either adjuvant intra-arterial chemotherapy in combination with 
radiotherapy (CAI/RT) (group A) or no adjuvant therapy (group B). 
Resection was by Whipple’s procedure or pylorus- preserving pancreaticoduodenectomy 
including removal of peripancreatic lymph nodes, lymph nodes in the hepatoduodenal ligament, 
and around the superior mesenteric vein including the tissue on the right side of the superior 
mesenteric artery for periampullary or pancreatic head tumors. A distal pancreatectomy plus 
splenectomy was performed in case of a tumor of the body of the pancreas. No extended lymph 
node resection was performed in this study.
Pathology was performed by one specialised pathologist and tumors were staged according to the 
UICC’s 2002 guidelines.30 Patients were eligible if they had histologically proven adenocarcinoma 
of the pancreas (UICC stages IA-III) or periampullary region (UICC stages IB- III, thus excluding T1N0 
tumors). Other eligibility criteria included an adequate functioning hematopoiesis (leucocytes 
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>3.5x109/l, thrombocytes >100x109/l), kidney (serum creatinine <2 mg/dl) and liver function (total 
serum bilirubin <2 mg/dl, partial thromboplastin time> 60%).
Duodenal carcinomas, neuroendocrine tumors and cystadenocarcinomas were excluded. Other 
exclusion criteria included age > 75 yrs, WHO performance status 3-4 or Karnofsky- Index 
<50%, serious active or uncontrolled infection or previous chemo- or radiotherapy. Patients 
with a vascular supply to the liver by an aberrant right hepatic artery deriving from the superior 
mesenteric artery were excluded as well as patients with previous or current malignancies at other 
sites other than carcinoma in situ of the cervix and adequately treated basal cell carcinoma of the 
skin, no effective contraception and child- bearing or breast feeding women. 
Patients were randomized when definitive pathology reports were available and patients had 
recovered from surgery. Patients were informed at first visit to the outpatient clinic and an 
informed consent was signed before the start of treatment. The treatment was planned to start 
after 6 weeks but within 12 weeks after surgery; thus patients with complications resulting in a 
prolonged hospital stay were not randomized.
Patients were restaged before the start of adjuvant treatment or during the first CAI course, 
before radiotherapy. All patients were closely followed up for disease progression with clinical 
and laboratory examinations every three months during the entire follow up period. Imaging 
techniques were performed every three months during the first two years after resection and 
every six months afterwards. An increased Ca 19.9 or CEA level or clinical signs of recurrence 
were indications for additional imaging. The follow up was continued for 5 years or up to decease 
of the patient. 
Adjuvant Treatment
Postoperative regional chemotherapy was performed by celiac axis infusion (CAI) with a planned 
total of 6 cycles or up to progressive disease. Treatment was delivered via a catheter placed 
angiographically through Seldinger’s technique via the femoral artery with the tip into the celiac 
trunk and left in place during the five treatment days of each cycle. To prevent thrombosis/
embolism, 20.000 IU/day of heparin were infused continuously via the catheter, exempt during 
drug infusion. One cycle consisted of mitoxantrone 10mg/m2 on day 1, folinic acid 170mg/m2 
directly followed by 5-fluorouracil 600mg/m2 on days 2-4, and cisplatinum 60mg/m2 on day 5. 
During and after infusion, toxicity was closely monitored according to WHO criteria, and doses 
were reduced by 20% in case of toxic events >WHO II. If the catheter could not be placed, the 
drug regimen was delivered intravenously (iv.) with a dose reduction of 20%. 
Two weeks after the first CAI cycle, radiotherapy was started. Radiotherapy was delivered according 
to the guidelines of the International Commission on Radiation Units and Measurements ICRU 50. 
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A total dose (TD) of 54 Gray (Gy) was delivered in single doses (SD) of 1.8 Gy 5 days a week using 
a 3 or 4-field technique. The minimum and maximum doses in the target volume was specified. 
Three weeks after finishing radiotherapy CAI was restarted up to a total of 6 cycles (including the 
first cycle given before radiotherapy) with an interval of 4 weeks between each cycle.
Treatment was discontinued if local or systemic tumor progression occurred, in case of irreversible 
toxicities WHO III or WHO IV, in case of intolerable side effects that could not be controlled by 
dose reductions or on the patient’s demand. 
Outcome measures and statistical analysis
Power calculations had led to a total of 120 patients in each group. However, several important 
clinical trials demonstrated a survival benefit of adjuvant chemotherapy after curative surgery 
which was not yet reported when this study was initiated.6, 23 Since our control group (observation 
group) did not receive any form of adjuvant treatment it was considered unethical to continue to 
include patients. The decision to stop inclusion was not based on outcome data.
The primary endpoint was overall survival time. Analysis was done with the Statistical Package for 
the Social Sciences version 10.1 (SPSS). Survival curves were computed according to the Kaplan 
Meier method from the date of randomization until the date of death from any cause or censored 
at the last follow up and median survival was calculated based on the curve. Comparison of 
survival curves was done with the log-rank test.
Secondary endpoints were toxicity of treatment and disease free survival defined as the time 
between randomization and local or distant recurrence on diagnostic imaging and local recurrence 
or hepatic progression rates. Patients were stratified for tumor type. Analyses were performed on 
an intention-to-treat basis. 
Our local ethics committee approved this open prospective randomized controlled trial. 
RESULTS
Patients
Between June 2000 and March 2007, 256 pancreaticoduodenectomies were performed. One 
specialized pathologist reviewed all resection specimens. One hundred thirty six patients were 
excluded for adjuvant treatment because of benign, neuroendocrine or cystic lesions (n=54), 
patient related factors (n=29) such as age (n=17), patient’s refusal (n=6), poor mental status 
(n=2), language related problems (n=2) or an aberrant right hepatic artery (n=2) or postoperative 
complications (n=23), other primary tumors (n=19), other neo or adjuvant therapies (n=5) and T1 
or metastatic disease (n=6). 
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After excluding these patients, 120 patients with resected pancreatic or periampullary (distal 
common bile duct or papilla of Vater) adenocarcinoma were eligible. Fifty-nine patients were 
randomized to the chemoradiation group (group A) and 61 patients to the surgery alone group 
(group B). Baseline characteristics were similar among the groups except for a possible relevant 
difference in mean age (60 years in group A vs. 66 years in group B; p< 0.01) and histopathological 
grading (more poorly differentiated tumors in the CAI/RT group; p=0.021) (Table 1). 
Table 1. Baseline Characteristics of Eligible Patients:
Characteristics CAI/RT
N= 59
Observation
N= 61
p-value
Median age (yr) (range) 62 (33-75) 69 (36-79) <0.001
Sex; number (%)
    Male
    Female
26 (44)
33 (56)
32 (53)
29 (47)
n.s.
n.s.
Type of surgery; number (%)
    Whipple’s procedure
    PPPD
    Distal pancreatectomy
16 (27)
43 (73)
0 (0)
14 (23)
46 (75)
1  (2)
n.s.
n.s.
n.s.
Days from surgery to randomization (range) 27 (15-70) 29 (15-57) n.s.
Karnofsky performance score; median (range) 90 (80-100) 90 (80-100) n.s
Pathologic diagnosis; number (%)
    Pancreatic head
    Periampullary cancer
31 (53)
28 (47)
31 (51)
30 (49)
n.s
n.s.
T category; number (%)
   (pancreatic head)
    T2
    T3
    T4
2 (7)
28 (90)
1 (3)
3 (10)
24 (77)
4 (13)
n.s.
n.s.
n.s.
T category; number (%)
   (periampullary)
    T2
    T3
    T4
9 (32)
13 (47)
6 (21)
8 (27)
16 (53)
6 (20)
n.s.
n.s.
n.s.
N category; number (%)
   (pancreatic head)
    N0
    N1
13 (42)
18 (58)
16 (52)
15 (48)
n.s.
n.s.
N category; number (%)
   (periampullary)
    N0
    N1
12 (43)
16 (57)
12 (40)
18 (60)
n.s.
n.s.
Resection status; number (%)
    (pancreatic head) 
    R0
    R1
23 (74)
8 (26)
22 (71)
9 (29)
n.s.
n.s.
Resection status; number (%)
    (periampullary) 
    R0
    R1
23 (82)
5 (28)
29 (97)
1 (3)
n.s.
n.s.
Histopathological grading; number (%)
    Well differentiated
    Moderately differentiated
    Poorly differentiated
    Missing
6 (10)
34 (58)
18 (30)
1 (2)
7 (12)
45 (74)
8 (13)
1 (2)
n.s.
n.s.
0.021
n.s.
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Median time from resection to start of adjuvant treatment was 61 days (range 42-96 days). 
None of the patients were lost to follow up. Median follow up was 17 months for all patients 
range 2-78 months). For the patients still alive the median follow up was 30 months (range 4-78 
months).
Compliance and adverse effects
Seven patients randomized to group A either refused treatment (n=3), were ineligible because 
of liver metastases detected on the re-staging CT scan (n=3) or died (n=1) because of congestive 
heart failure while waiting for start of treatment. Hence, of the 59 patients assigned to CAI/RT a 
total of 52 patients actually received adjuvant treatment. In the statistical analysis, all 59 patients 
remained in the assigned group according to the intention to treat principle. 
Overall grade 3 and 4 toxicity is shown in Table 2. Adverse toxic events caused discontinuation 
in 13/ 52 patients (25%), in 7 with pancreatic cancer and in 6 with periampullary cancer. Ten 
patients suffered from hematological toxicity and the three others because from a skin rash, a 
gastrointestinal bleeding and a gastrointestinal ulcer. Of these 13 patients, three had to stop 
treatment after CAI-I, four after CAI-II, one after CAI-III, three after CAI-IV and two after CAI-V. 
Progressive disease caused termination in 11 patients (21%), in 9 with pancreatic cancer and in 
2 with periampullary cancer. Three patients after CAI-I, II and III and two patients after CAI-IV. 
Three patients (6%) refused to continue treatment after CAI-I, II or III. In three other patients 
treatment was postponed and finally stopped because of sever hyperglycaemia after CAI-I, 
cerebral infarction after CAI-IV or a lethal myocardial infarction after CAI-I. Six hundred twenty 
celiac axis catheterisations were performed and catheter luxations were seen in 14% of the 
placements. Catheter related complications were seen in five patients resulting in discontinuation 
of treatment after CAI-II in one patient. A subtotal stenosis of the celiac trunk was found in three 
patients leading to intravenous administration of chemotherapy. A dissection of the common 
femoral artery was caused in one patients necessitating stenting and an external iliac artery 
dissection in another necessitating thrombectomy and a patch angioplasty. 
Thirty six per cent (21/ 59) of all patients in the CAI/RT group received all 6 cycles including 
radiotherapy as specified in the protocol: six patients with pancreatic cancer and 15 patients with 
periampullary cancer. The median number of cycles administered in these 59 patients was 3. For 
the patients with pancreatic tumors the median number of cycles was three and the patients with 
periampullary tumors received median six cycles.
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Table 2: Recurrence pattern
Chemoradiotherapy 
Number (%)
Observation 
Number (%)
P value
No progression
         Pancreatic cancer 9 (29) 4 (13) n.s. 
         Periampullary cancer 13 (46) 7 (23) n.s. 
Alive with disease
         Pancreatic cancer 2 (6) 3 (10) n.s.
         Periampullary cancer 3 (11) 4 (13) n.s.
Dead of disease
         Pancreatic cancer 20 (65) 24 (77) n.s.
         Periampullary cancer 12 (43) 19 (63) n.s.
First site of progression
        Local recurrence
                Pancreatic cancer 6 (19) 11 (35) n.s.
                Periampullary cancer 5 (18) 3 (10) n.s.
        Liver
                Pancreatic cancer 8 (26) 7 (23) n.s.
                Periampullary cancer 4 (14) 11 (37) n.s.
        Both
                Pancreatic cancer 3 (10) 2 (6) n.s.
                Periampullary cancer 1 (4) 2 (7) n.s.
        Other
                Pancreatic cancer 5 (16) 7 (23) n.s.
                Periampullary cancer 5 (18) 7 (23) n.s.
Overall development of distant progression
        Liver
                Pancreatic cancer 14 (45) 15 (48) n.s.
                Periampullary cancer 8 (29) 17 (57) 0.021
        Lung
                Pancreatic cancer 7 (23) 5 (16) n.s.
                Periampullary cancer 3 (11) 5 (17) n.s.
        Other
                Pancreatic cancer 2 (6) 7 (23)
                Periampullary cancer 2 (7) 5 (17)
Time to Progression
Progressive disease was seen in 87 of the 120 patients. Progressive disease developed in 37 
patients in the CAI/RT group, and in 50 patients in the surgery alone group. Median time until 
progression was 12 months in the CAI/RT group vs. 7 months in the surgery alone group (p=0.015; 
Figure 1). The distribution of progressive disease is shown in Table 3.
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Figure 1: Time to progression after CAI/RT vs. observation (p=0.015). The numbers below the 
figure denote the numbers at risk.
Table 3: Grade 3 and 4 toxicity
Grade 3 Grade 4
Toxicity Number (%) Number (%)
Hematologic
Hemoglobin 1 (2) 0 (0)
Leucocytes 10 (20) 1 (2)
Platelets 0 (0) 1 (2)
Non-hematologic
Nausea 0 (0) 0 (0)
Vomiting 3 (6) 0 (0)
Diarrhea 0 (0) 0 (0)
Alopecia 0 (0) 0 (0)
Fatigue 0 (0) 0 (0)
Stratification for tumor type, i.e. periampullary vs. pancreas carcinoma, shows a considerable 
difference in recurrence pattern. Patients with periampullary tumors develop significantly less 
liver metastases after CAI/RT (log-rank p=0.021), without significant effect on prevention of 
locoregional recurrence (log-rank p=0.294). In pancreatic tumors on the other hand CAI/RT 
had no significant effect on the development of liver metastases (log-rank p=0.755) or on local 
recurrence rate (log-rank p=0.12). 
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Overall Survival
Survival analysis was based on 82 deaths, of which 72 deaths were cancer related. 
Overall thirty-eight patients died in the CAI/RT group as compared to 44 in the surgery alone 
group. There was no significant survival benefit in the treatment group. After CAI/RT, median 
survival was 19 months compared to 18 months after surgery alone (p=0.25; Figure 2). Survival 
in the three patients with IV continuation of treatment was 5, 7 and 39 months respectively.
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Figure 2: Overall survival after CAI/RT vs. observation (p=0.25). The numbers below the figure 
denote the numbers at risk. 
Ten patients died of non-cancer related causes: Eight patients in group A because of a cerebral 
infarction (n=2), hypo- and hyperglycaemic coma (n=2), myocardial infarction (n=2), Aspergillus 
pneumonia (n=1) and a gastric bleeding (n=1) and two patients in group B caused by a gastric 
bleeding (n=1) and a traffic accident (n=1). There was a clear trend in cancer specific survival 
between the two treatment groups (log-rank p= 0.05; Figure 3).
Regardless of treatment group, a significant better overall survival was found in periampullary 
tumors vs. pancreatic cancer (median survival was 27 vs. 14 months; p< 0.001) (Figure 4). 
However, no significant benefit of treatment on overall survival is seen in either subgroup (p= 
0.66 for pancreatic cancer and p= 0.15 for periampullary tumors) (Figure 5a-b).
For all endpoints analyzed, we found no effect of age. The by chance imbalance regarding age 
between the two treatment groups did not affect our results.
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Figure 3: Cancer related survival after CAI/RT vs. observation (p=0.052). The numbers below the 
figure denote the numbers at risk. 
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Figure 4: Overall survival in pancreatic cancer vs. periampullary tumors regardless of treatment 
(p<0.001). The numbers below the figure denote the numbers at risk. 
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Figure 5a-b: Overall survival after CAI/RT vs. observation in pancreatic carcinoma (a; p=0.66) and 
periampullary tumors (b; p=0.15). The numbers below the figure denote the numbers at 
risk. 
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DISCUSSION
This randomized controlled trial shows a significant improvement of time to progression after 
intra-arterial chemoradiotherapy compared to observation for both pancreatic as well as 
periampullary tumors. Most effect is seen in periampullary tumors were liver metastases are 
significantly reduced. These promising effects on recurrence do not result in a prolonged overall 
survival, not even after stratification for tumor type. However, cancer related survival seems to 
improve after intra-arterial chemoradiation (p=0.05). Toxicity of CAI/RT was acceptable (25%) 
and catheter related problems necessitating intervention occurred in two patients.
Surgery is still considered to be the mainstay of treatment for patients with resectable pancreatic 
tumors. Mortality and morbidity rates have declined over the years without subsequent effect on 
5-year survival.31Adjuvant therapies were administered to improve this 5-year survival, so far with 
disappointing results. Where only the ESPAC-1 showed an disputable overall survival benefit, all 
other published randomized controlled trials showed only improved disease free survival.2, 6, 20, 32 
The median survival we presented for all patients after CAI/RT or observation (19 or 18 months) 
was comparable with the results of the ESPAC-1 trial2, 23 (median survival depending on the 
treatment arm varying between 13.9 and 21.6 months) and the CONKO-1 trial6 (median survival 
of 22.1 months after gemcitabine and 20.2 months after observation). However these trials 
pretended to include only patients with pancreatic cancer. We describe the results of both patients 
with pancreatic (median survival 14 months) and periampullary (median survival 27 months) 
tumors. In this trial a standardized system of pathologic assessment for quality control was used. 
One single, specialized pathologist reviewed all specimens to differentiate between pancreatic 
and periampullary tumors. In both the ESPAC-1 and CONKO-1 trial no central pathology control 
was performed probable leading to the inclusion of patients with periampullary tumors as well. 
Furthermore in this trial we performed a restaging before the start of the radiotherapy, which in 
our opinion is essential to evaluate the result of adjuvant treatment.
However, the figures presented are not actual median survival figures. We included patients after 
recovery from surgery and although peri-operative mortality is low in our center, this could have 
led to a bias. 
The similar survival figures illustrate the minor progression achieved on overall survival, despite 
large volume multicenter trials. Currently applied treatment strategies are based on generally 
accepted agents such as 5- FU, gemcitabine possibly in combination with cisplatinum. These 
regimens might need reconsideration since the Virginia Mason, Seattle, USA group reported 
such encouraging results combining interferon (IFN) alpha with 5-FU, cisplatinum, and radiation 
therapy after pancreatoduodenectomy. They reported a 2-year survival rate of 64% and a 5-year 
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survival rate of 55% in patients with high-risk resected pancreatic adenocarcinoma.33 These 
promising results are currently reinvestigated in the phase III CapRI study.34 Results of this study 
are expected shortly and might give an indication whether immunomodulatory drugs should 
be added to the standard adjuvant regimens and enhance the effect of both chemo- and/or 
radiation therapy. In vitro there is clear evidence that differential expression levels and distribution 
of the interferon receptor subunits play a role in the regulation of the response to type I IFN 
therapy in pancreatic cancer. Future studies should investigate whether the intensity, subcellular 
localization, and distribution of these receptor subtypes may predict the response to therapy with 
different interferons in pancreatic cancer.35
An important outcome of our study is the significance of differentiating between periampullary 
tumors and pancreatic carcinoma. Patients operated for periampullary tumors survived 
significantly longer compared to patients with pancreatic cancer (27 vs. 14 months; p<0.001) and 
developed less liver metastases after intra-arterial chemotherapy and radiotherapy compared to 
observation (log-rank p<0.03). Patients with pancreatic cancer developed more local recurrences 
compared to periampullary tumors (log-rank p<0.01) but CAI/RT had no significant effect on local 
recurrence rate (log-rank p=0.12) nor on the development of liver metastases compared to the 
observation group (log-rank p=0.755). Consequently, no effect of CAI/RT was found on overall 
survival. This supports the conclusion of our EORTC trial that there is no role for chemoradiation 
in the prevention of local recurrence.20, 21 
The choice for the less frequently used mitoxantrone was based on the study of Beger et al 27, 
revealing tolerable toxicity after intra-arterial admission if combined with 5-FU and cisplatinum. 
In addition, mitoxantrone is active in regional chemotherapeutics protocols like hepatic arterial 
infusion of colorectal liver metastases.36 If we compare our results with the results published by 
Beger, the effect of CAI/RT on the development of liver metastases was confirmed, however where 
they found a consequent survival benefit, where we did not. One of the factors might be that 
eventually only 21 (36%) patients received treatment as stated in the protocol. However, there is 
no consensus on the number of cycles gaining the optimal effect of intra-arterial chemotherapy. 
Seventy three percent of the patients (n=42) for instance received 2 cycles or more of intra-arterial 
chemotherapy combined with radiotherapy. Based on the intention to treat principle, even with 
only 21 patients receiving full adjuvant treatment, there is a significant effect on the development 
of liver metastases in periampullary tumors and time to progression. Furthermore, in considerable 
number of patients, especially pancreatic cancer patients, adjuvant treatment was stopped due to 
progressive disease, which explains the low number of patients receiving 6 cycles of CAI. 
There were some protocol violations. One patient was included aged 79 years because of younger 
biological age. And in one patient, due to the holiday, treatment was started after 96 days. We 
found it unethical to withdraw this patient from the explained treatment arm. 
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Considering survival after treatment of patients with periampullary tumors, the number of 
patients in both groups (28 in group A vs. 30 in group B) was not sufficient to prove a significant 
survival benefit after treatment, but based on the Kaplan Meier curve (Figure 5b) there appears 
to be an effect of intra-arterial chemoradiation. It seems likely that after a longer follow up 
a significant survival benefit after CAI/RT in periampullary tumors will be found. However we 
decided to terminate the trial because of trials published during the inclusion period suggesting 
it is no longer ethical to have an observation arm and gemcitabine should be standard of care. 
A complicating factor was the poor patient recruitment, since this trial was designed to include 
patients in the University Hospital of Ulm as well, but recruitment never started there due to 
logistic problems. Not surprisingly, for pancreatic carcinoma no overall or disease free survival 
benefit was found since CAI/RT did not reduce local recurrence nor the development of liver 
metastases. The imbalance in histopathological grading in favor of the observation group (more 
poorly differentiated tumors in the CAI/RT group; p=0.021) might have lead to an underestimation 
of the effect of CAI/RT on overall as well as on disease free survival.
Since differentiating between pancreatic and periampullary cancer pre-operatively by CT 
scanning or endoscopic ultrasound appears to be difficult if not impossible, new treatment 
schedules including neoadjuvant therapy for only true pancreatic cancers will be difficult to 
develop. Nowadays the final diagnosis is based on histopathological findings of the operative 
specimen, thus requiring resection and consequently eliminating the possibility of tumor specific 
neoadjuvant treatment. However future improvements in CT scanning techniques, endoscopic 
ultrasound experience and DNA analysis might facilitate pre-operative differentiation.
Remarkably, more non-cancer related deaths occurred in the CAI/RT group. Cause of this can be 
twofold: either therapy caused more deaths, or patients in the observation arm were followed less 
closely. However, death occurred over two months after finishing/ending therapy and patients in 
both arms were monitored equally. Speculating, patients in the treatment arm were capable of 
dying from other causes because they survived their cancer, but than you would have expected 
a survival difference. 
One concern that has not been mentioned so far is the impact this treatment could have on the 
quality of life. This regime is quite intense, necessitating hospital admissions for every cycle and 
visits to the outpatient clinic daily during radiotherapy. Because we realize it is not ethical to give 
such an intense treatment to patients with a short prognosis thereby reducing the quality of life, 
we concomitantly performed a quality of life investigation. Preliminary results of the analysis of 
quality of life forms, reveals that at least there is no detrimental effect of this treatment on quality 
of life in general. One of the causes can be that although toxicity occurs in 25% of the patients, 
this is mainly of hematological origin. However, definite results will be presented in the future.
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In conclusion, CAI/RT does result in a significant increase in disease free survival mostly because 
significantly less liver metastases developed in periampullary tumors after intra-arterial therapy. 
A clear trend of adjuvant CAI/RT after curative resection was found for overall cancer related 
survival (p=0.05) and for overall survival in periampullary tumors (p=0.15) but not for overall 
survival in all patients (p=0.25). Again, no benefit of chemoradiation on local recurrence in 
neither pancreatic nor periampullary cancers was found. In our opinion, differentiating between 
periampullary and pancreatic tumors is of paramount importance for further treatment strategies 
with periampullary tumors being most prone to intra-arterial chemoradiotherapy. For pancreatic 
cancer another regime has to be considered. 
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ABSTRACT
Background: Adjuvant therapies in pancreatic and periampullary cancer have been shown to 
achieve only marginal survival benefit. In this randomized controlled trial, 120 patients with 
resected pancreatic or periampullary cancer received either adjuvant celiac axis infusion combined 
with radiotherapy (CAI/RT) or no adjuvant treatment.  
Aim of the study: To compare Quality of Life (QoL) in patients receiving CAI/RT after 
pancreatoduodenectomy with QoL in patients without adjuvant treatment.
Methods: During and after CAI/RT, QoL was assessed using the European Organization for 
Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) every 3 
months during the first 24 months after randomization. 
Results: Eighty-six per cent (n=103) of the patients completed one or more questionnaires. In 
total, 355 questionnaires were completed. CAI/RT did not impair physical, emotional or social 
functioning. During and after CAI/ RT, patients had significantly less pain (p=0.02) and less 
nausea and vomiting (p=0.01). Overall QoL (global functioning) tended to be better (p=0.08) 
after CAI/RT. 
Conclusion: Over a period of 24 months, CAI/RT improved quality of life compared to observation 
alone in patients with resected pancreatic and periampullary cancer. This beneficial effect of CAI/
RT is most prominent in the latter half of the follow-up. 
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INTRODUCTION
Pancreatic cancer is currently one of the world’s most fatal malignant diseases and ranks fourth 
in cancer related mortality.1 Even after radical resection, median survival time is 12 - 15 months2, 
3 with 5-year survival rate ranging from 5% to 25%.2, 4-6
Considering this short life expectancy after radical resection and morbidity related to a 
pancreatoduodenectomy7, the value of resection has been discussed. However, several trials 
showed that after pancreatoduodenectomy quality of life (QoL) returned to pre-operative values 
three months after surgery8 or was even better than before surgery measured up to 6 months 
after surgery in patients with localized pancreatic cancer.9, 10 However, compared to laparoscopic 
surgery for a benign cause, i.e. laparoscopic cholecystectomy, patients after pylorus preserving 
pancreatoduodenectomy for pancreatic adenocarcinoma have a significantly worse quality of 
life.11 This deleterious effect on the quality of life might be explained by both the extend of the 
surgery as well as the primary indication for surgery, i.e. a benign vs. a malign lesion. 
To improve survival after pancreatoduodenectomy in patients with pancreatic tumors as well 
as periampullary tumors, several clinical trials have been performed studying the efficacy of 
chemotherapy and/or radiotherapy. Most of the studies investigated improvement of disease 
free or overall survival by adjuvant therapy.2, 6, 12-17 In only two randomized controlled trials, the 
effect of adjuvant chemotherapy or chemoradiotherapy on quality of life was also measured. 
The ESPAC-I trial found similar quality of life after 5-FU based chemotherapy (425 mg/m2 on five 
consecutive days for six cycles) vs. no chemotherapy and 5-FU based chemoradiotherapy (500 mg/
m2 on the first three days of each week of radiotherapy (10x 2 Gray)) vs. no chemoradiotherapy. 
The CONKO-001 trail compared chemotherapy (6 cycles of three weekly infusions of gemcitabine 
1000 mg/m2) with observation and found no adverse effect on quality of life.6, 18  
In a randomized controlled trial we compared intra-arterial chemotherapy plus radiotherapy (CAI/
RT) with observation after pancreatoduodenectomy in patients with periampullary or pancreatic 
cancer.19 This therapy involves six separate weeks of hospitalization, indwelling catheters, several 
angiographies, six weeks of daily radiotherapy on outpatient basis and considerable toxicity, 
mainly of hematological origin; the therapeutic results were reported previously.
To investigate whether the efficacy of this treatment was counterbalanced with detrimental 
effects on quality of life, analysis of the quality of life was a predefined secondary endpoint. The 
results of the quality of life analysis are described in this report. 
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METHODS
Because the trial design has been mentioned extensively before, we summarize only the main 
aspects.19
Study design
After pancreatoduodenectomy, patients with histological proven adenocarcinoma of the pancreas 
or the periampullary region were randomly assigned to receive either adjuvant intra-arterial 
chemotherapy combined with radiotherapy (CAI/RT) or observation. Intra-arterial chemotherapy 
consisted of 6 cycles of mitoxantrone (10mg/m2 on day 1), 5-fluorouracil+ folinic acid (600mg/m2 
+170mg/m2 on days 2-4) and cisplatinum (60mg/m2 on day 5); 54 Gray (total dose) radiotherapy 
was also given. During each cycle of chemotherapy, patients were admitted to hospital, had an 
indwelling intra-arterial catheter, and were obliged to stay in bed for the entire week. During 
radiotherapy, patients were treated on an outpatient basis, receiving 1.8 Gray each weekday 
for 6 weeks. Including intervals, the entire schedule lasted over 8 months. None of the patients 
received further chemotherapy or radiotherapy in case of recurrence.
Quality of Life Assessments 
Quality of life was measured using the European Organization for Research and Treatment of 
Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) version 3.0 20 which is a 30-item 
self-reporting questionnaire developed to assess the quality of life of cancer patients. It is grouped 
into five functional subscales (role, physical, cognitive, emotional and social functioning). It also 
contains three multi-item symptom scales (fatigue, pain, and nausea and vomiting); individual 
questions concerning common symptoms in cancer patients (dyspnea, insomnia, appetite loss, 
constipation, diarrhea, and financial difficulties); and two questions assessing overall quality of 
life (global functioning). 
Quality of life was assessed every 3 months in the first 24 months after randomization. The first 
quality of life questionnaire was filled out at three months and was used as baseline. The quality 
of life forms were sent to the patients prior to an outpatient clinic visit, where filled out forms 
were collected. 
Outcome measures and statistical analysis
Survival curves were computed according to the Kaplan Meier method from the date of 
randomization until the date of death from any cause or censored at the last follow-up. Median 
survival was calculated on the basis of the curve. Survival curves were compared using the log-
rank test. 
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All scores from the EORTC QLQ-C30 (version 3) questionnaire were transformed to a 0-100 scale 
using a linear transformation.20 Higher scores for a functional scale represent a higher level of 
functioning, i.e. a better state of the patient. Conversely, higher scores for symptoms indicate a 
higher level of complaints. 
Nine scales of the EORTC QLQ-C30 were selected a priori for this analysis: physical, emotional 
and social functioning; fatigue; pain; nausea and vomiting; loss of appetite; diarrhea; and global 
functioning.
Compliance was calculated as the number of completed questionnaires expressed as a percentage 
of the number of questionnaires expected (per time interval). Fifty per cent of the standard 
deviation of any QoL tool equivalent to 8-10 points is usually considered as clinically significant 21
All quality of life scales were compared between randomized arms with repeated measurement 
ANOVA using SAS PROC MIXED (version 8.2). For all scales it was evaluated whether the treatment 
effect differed between time points of assessment with interaction terms. Other analyses were 
done using SPSS version 11.5. All evaluations were done using an intention to treat basis, and 
p=0.05 (two-sided) was considered the limit of significance.
RESULTS
Summary of Clinical Results19
Between June 2000 and March 2007, 120 patients with resected pancreatic or periampullary 
adenocarcinoma were randomized to intra-arterial chemoradiotherapy (n=59) or observation 
(n=61). Table 1 shows the characteristics of these patients. The median follow up was 17 months. 
Thirty six per cent (21/ 59) of all patients in the CAI/RT group received all 6 cycles including 
radiotherapy as specified in the protocol. Causes for discontinuation of treatment as planned 
were adverse toxic events in 13/ 52 patients (25%), progressive disease in 11 patients (21%), 
patient’s refusal in 3 patients (6%) and co-morbidity in three others. Six hundred twenty celiac 
axis catheterizations were performed and catheter luxations were seen in 14% of the placements. 
After CAI/RT patients had a significantly prolonged time to progression (12 vs. 7 months; log-rank 
p<0.02). Overall, no significant survival benefit was seen after CAI/RT compared to observation 
(median 19 vs. 18 months; p=0.25) although cancer specific survival tended towards significance 
(29 vs. 18 months; log-rank p= 0.052). 
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Table 1. Baseline Characteristics of Eligible Patients:
Characteristics
CAI/RT
N= 59
Observation
N= 61
p-value
Median age (yr) (range) 62 (33-75) 69 (36-79) <0.001
Sex; number (%)
    Male
    Female
26 (44)
33 (56)
32 (53)
29 (47)
n.s.
n.s.
Type of surgery; number (%)
    Whipple’s procedure
    PPPD
    Distal pancreatectomy
16 (27)
43 (73)
0 (0)
14 (23)
46 (75)
1  (2)
n.s.
n.s.
n.s.
Days from surgery to randomization (range) 27 (15-70) 29 (15-57) n.s.
Karnofsky performance score; median (range) 90 (80-100) 90 (80-100) n.s
Pathologic diagnosis; number (%)
    Pancreatic head
    Periampullary cancer
31 (53)
28 (47)
31 (51)
30 (49)
n.s
n.s.
T category; number (%)
   (pancreatic head)
    T2
    T3
    T4
2 (7)
28 (90)
1 (3)
3 (10)
24 (77)
4 (13)
n.s.
n.s.
n.s.
T category; number (%)
   (periampullary)
    T2
    T3
    T4
9 (32)
13 (47)
6 (21)
8 (27)
16 (53)
6 (20)
n.s.
n.s.
n.s.
N category; number (%)
   (pancreatic head)
    N0
    N1
13 (42)
18 (58)
16 (52)
15 (48)
n.s.
n.s.
N category; number (%)
   (periampullary)
    N0
    N1
12 (43)
16 (57)
12 (40)
18 (60)
n.s.
n.s.
Resection status; number (%)
    (pancreatic head) 
    R0
    R1
23 (74)
8 (26)
22 (71)
9 (29)
n.s.
n.s.
Resection status; number (%)
    (periampullary) 
    R0
    R1
23 (82)
5 (28)
29 (97)
1 (3)
n.s.
n.s.
Histopathological grading; number (%)
    Well differentiated
    Moderately differentiated
    Poorly differentiated
    Missing
6 (10)
34 (58)
18 (30)
1 (2)
7 (12)
45 (74)
8 (13)
  (2)
n.s.
n.s.
0.021
n.s.
Abbreviations: CAI/RT= intra-arterial chemoradiotherapy, PPPD= pylorus preserving pancraetoduodenectomy
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Quality of Life
Table 2 shows the proportion of patients with assessable quality of life forms in each time interval. 
Eighty-six per cent (n=103) of the patients completed one or more questionnaires, 51 in the 
treatment arm and 52 in the observation arm with 71% of the patients completing at least two 
questionnaires. A total of 355 questionnaires were completed, with a median number of 4 (range 
1-7) in patients undergoing CAI/RT and a median number of 3 (range 1-7) in patients in the 
observation arm. Overall, 60% of the expected questionnaires were completed and assessable 
for analysis. The rate of assessable questionnaires decreased over time, with more available forms 
in the CAI/RT arm in the first 6 months, but no difference after the end of the treatment. The 
decrease in the number of questionnaires was not related to toxicity. The median number of 
questionnaires obtained from the 13 patients suffering from toxicity was 5.
Table 2. Response rates/ compliance
CAI/RT Observation p-value
Patients in time 
window (number)
Patients with 
assessable 
questionnaires (%)
Patients in time 
window (number)
Patients with 
assessable 
questionnaires (%)
3 months 57 81 59 63 <0.05
6 months 52 87 56 43 <0.01
9 months 45 73 49 59 n.s.
12 months 36 44 40 53 n.s.
15 months 34 50 32 59 n.s.
18 months 29 48 23 52 n.s.
21 months 24 63 20 55 n.s.
24 months 21 43 16 44 n.s.
Abbreviations: CAI/RT= intra-arterial chemoradiotherapy.
After CAI/RT no significantly better physical, emotional and social functioning scores were found 
during the total observation period, although physical functioning tended towards significance 
(p=0.10; mean difference 5.4 points) in favor of the treatment arm (Table 3 and Figure 1). 
Although the treatment effect did not significantly differ between time points, better mean 
values were found for CAI/RT at 15 and 18 months (both p<0.05). 
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Table 3. Quality of Life scores
Adjusted mean values* Difference 95% CI Difference Overall 
p-valueCAI/RT Observation
FUNCTIONING SCALES
Social Functioning 85 81 4.0 -3.7 to 11.5 0.30
Physical Functioning 85 79 5.4 -1.0 to 11.8 0.10
Emotional Functioning 81 75 6.3 -1.2 to 13.9 0.11
SYMPTOM SCALES
Pain 17 26 -9.7 -17.9 to -1.5 0.02
Fatigue 25 30 -6.3 -14.2 to 1.5 0.12
Nausea & Vomiting 6 12 -5.9 -10.4 to -1.4 0.01
Loss of appetite 11 16 -4.4 -11.1 to 2.3 0.20
Diarrhea 11 16 -5.0 -12.5 to 2.6 0.20
OVERALL Quality of Life
Global functioning 73 66 6.5 -0.6 to 13.6 0.08
*Adjusted for age and gender
Abbreviations: CAI/RT= intra-arterial chemoradiotherapy, 95% CI= 95% confidence interval.
Figure 1:  Mean EORTC QLQ-C30 score on physical functioning after adjuvant intra-arterial 
chemotherapy combined with radiotherapy or observation in resected pancreatic and 
periampullary cancer according to the number of months after randomization. Note 
that a higher score corresponds with a better physical functioning. Error bars represent 
standard errors. Denoted p -value denotes overall p-value.
For the symptom scales, patients had significantly less pain (overall p=0.02; mean difference 
9.7 points) (Figure 2). This difference was most outspoken at time points 15 and 18 months 
(both p<0.05). There was also significantly less nausea and vomiting (p=0.01; mean difference 
5.9 points) after CAI/ RT with the most eminent difference at 15 and 24 months (both p<0.05) 
(Figure 3). 
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Figure 2:  Mean EORTC QLQ-C30 pain scores after adjuvant intra-arterial chemotherapy combined 
with radiotherapy and observation in resected pancreatic and periampullary cancer. Note 
that a higher score corresponds with more pain.
Figure 3:  Mean EORTC QLQ-C30 nausea and vomiting scores after adjuvant intra-arterial 
chemotherapy combined with radiotherapy and observation in resected pancreatic 
and periampullary cancer. Note that a higher score corresponds with more nausea and 
vomiting.
For the other symptom scales there was no significant difference between randomized arms. 
Especially fatigue did not occur more often during or after CAI/RT (p=0.12; mean difference 6.3 
points) (Figure 4). 
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Figure 4:  Mean EORTC QLQ-C30 fatigue scores after adjuvant intra-arterial chemotherapy 
combined with radiotherapy and observation in resected pancreatic and periampullary 
cancer. Note that a higher score corresponds with more fatigue.
Toxicity occurred in 13 patients and did not negatively influence quality of life compared to 
patients receiving the entire schedule or patients in the observation arm.
Overall quality of life (global functioning) tended towards significance (p=0.08; mean difference 
6.5 points) in favor of the CAI/RT arm (Figure 5). 
Figure 5:  Mean EORTC QLQ-C30 scores on overall quality of life (global functioning) after adjuvant 
intra-arterial chemotherapy combined with radiotherapy and observation in resected 
pancreatic and periampullary cancer. Note that a higher score corresponds with a better 
overall quality of life.
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DISCUSSION
In this randomized controlled trial19, we compared intra-arterial chemoradiotherapy (CAI/RT) 
with observation after R0/R1 pancreatoduodenectomy. Patients randomized to the treatment 
arm received 6 cycles of chemotherapy and 30x 1.8 Gray radiation. Including intervals, the entire 
schedule lasted a minimum of 8 months with intermittent hospital admissions. Although there was 
no overall survival benefit after intra-arterial chemoradiotherapy, cancer-related survival tended 
to be better in the treatment arm. Intra-arterial chemoradiotherapy also significantly extended 
time to progression in all patients and reduced the number of liver metastases in patients with 
periampullary tumors. 
In this study, quality of life measured according to the EORTC QLQ-C30 principles was improved 
from baseline after CAI/RT for all endpoints analyzed. On all functioning scales higher mean 
scores indicating better functioning were found, although none of these scores were significant. 
For all symptom scores, patients reported fewer complaints, leading to lower mean scores. For 
pain and nausea and vomiting, these scores were significantly lower after CAI/RT than the scores 
in the observation arm for the first 24 months after randomization. For pain score, for which there 
was a mean difference of 9.7 points between CAI/RT and surgery alone, this difference was also 
clinically relevant. For all QoL scores, the difference between the CAI/RT arm and the observation 
arm was constant over the 24 months, but the effect of CAI/RT on QoL was most apparent 12- 24 
months after the start of therapy. In the first 12 months of quality of life assessment, i.e. during 
CAI/RT, symptoms such as fatigue, nausea and vomiting or pain did not occur more often. Overall 
quality of life tended to be better after CAI/RT (p=0.08).
A limitation of our study is the absence of questionaires at baseline. Therefore we could not 
evaluate changes from baseline, which are expected to give more precise results. Our results are 
valid though because from the randomisation one may expect that the baseline quality of life 
is comparable between both groups. Also the number of questionaires returned per patient is 
comparable.
One important feature of quality of life assessment is that it is subjective. This is particularly 
relevant as CAI/RT might be expected to negatively influence patient’s quality of life due to the 
impact of the number and length of hospital admissions, outpatient visits and the toxicity of the 
therapy itself. 
However, chemotherapy and/or radiotherapy is not necessarily associated with an impaired 
quality of life. More effective therapies produce a better quality of life because minor tumor 
shrinkage relieves some of the symptoms, or because they produce a longer period without 
disease and thus less time involving the problems of recurrent disease and its treatment. Thus a 
longer or more toxic treatment is not always associated with lower quality of life. Quality of life 
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can even improve when therapy has no objective effect; this may be due to the placebo effect, 
to the provision of hope, or to the increased medical attention associated with being in a study. 
Neither are side-effects the major determinants of quality of life.22
Comparison of our results with previous randomized controlled trials on adjuvant therapies 
in pancreatic and periampullary cancer2, 6 shows that this is the first trial to demonstrate that 
adjuvant therapy benefited quality of life up to 24 months after resection. One of the reasons for 
this difference is that the CONKO-001 trial used the Spitzer Quality of Life Index, a questionnaire 
focusing on more non-specific quality of life parameters, such as daily activity, social support and 
mental well being. Our use of the EORTC QLQ-C30, which focuses both on functioning scales 
and on cancer-specific complaints such as pain, fatigue and nausea and vomiting, is important, as 
it is especially on these symptom scores that we found a beneficial difference for the CAI/RT arm. 
Although the ESPAC-1 trial also evaluated quality of life with the EORTC QLQ-C30 questionnaire, 
it produced a quality of life response percentage of 53%, and measured quality of life for only 
the first 12 months after resection. In our trial, the most noticeable differences in all quality of 
life dimensions occurred after these first 12 months. If the ESPAC-1 trial had continued to assess 
quality of life over a longer period, it might have found a similar difference, although this effect 
might also have been reduced by the two-by-two factorial design.
Since survival after adjuvant therapy for resected pancreatic or periampullary cancer has not 
lengthened substantially over the years, the aim of adjuvant therapy in these patients should at 
least be to improve the quality of life during the short remaining lifetime. We have shown that 
CAI/RT, although a demanding therapy, improves quality of life from baseline. We therefore state 
that it is incorrect to deny cancer patients intensive therapies only because they do not result in a 
significant survival benefit. One of the possible objective factors underlying this beneficial effect 
on the quality of life is the fact that time to progression is extended. Where patients with recurrent 
disease develop duodenal obstruction and especially pain, the postponement of recurrence leads 
to a longer complaint-free period and thus a higher quality of life. Because none of our patients 
were treated with chemotherapy or radiotherapy after recurrence, there is no treatment related 
effect causing a decline in quality of life in the second half of the follow up.  
In conclusion, 5-FU based intra-arterial chemotherapy combined with radiotherapy improves 
quality of life compared to observation alone in patients with resected pancreatic and periampullary 
cancers. Over a period of 24 months, patients suffer from significantly less pain and significantly 
less nausea and vomiting. This beneficial effect of CAI/RT is most prominent in the latter half of 
the follow-up and is probably caused by a delay in tumor recurrence and related symptoms. Given 
the disappointing effect on overall survival of adjuvant therapy after pancreatoduodenectomy, 
quality of life during this period is of eminent importance. Impairment in quality of life during or 
after treatment is no longer a reason to deny patients adjuvant therapies.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Quality of Life after CAI/RT vs Surgery Alone in Resectable Pancreatic and Periampullary Cancer  |  53
3
REFERENCES
1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57(1): 
43-66.
2. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, 
Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Buchler MW. Adjuvant 
chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. 
Lancet 2001;358(9293): 1576-1585.
3. Willett CG, Czito BG, Bendell JC. Adjuvant therapy of pancreatic cancer. Cancer J 2007;13(3): 185-
191.
4. Bassi C, Stocken DD, Olah A, Friess H, Buckels J, Hickey H, Dervenis C, Dunn JA, Deakin M, Carter R, 
Ghaneh P, Neoptolemos JP, Buchler MW. Influence of surgical resection and post-operative complications 
on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled 
trial. Dig Surg 2005;22(5): 353-363.
5. Kennedy EP, Yeo CJ. Pancreaticoduodenectomy with extended retroperitoneal lymphadenectomy for 
periampullary adenocarcinoma. Surg Oncol Clin N Am 2007;16(1): 157-176.
6. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart 
C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, 
Schmidt-Wolf I, Roll L, Doerken B, Riess H. Adjuvant chemotherapy with gemcitabine vs observation in 
patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. Jama 
2007;297(3): 267-277.
7. Fingerhut A, Vassiliu P, Dervenis C, Alexakis N, Leandros E. What is in a word: Pancreatoduodenectomy 
or pancreaticoduodenectomy? Surgery 2007;142(3): 428-429.
8. Nieveen van Dijkum EJ, Kuhlmann KF, Terwee CB, Obertop H, de Haes JC, Gouma DJ. Quality of life 
after curative or palliative surgical treatment of pancreatic and periampullary carcinoma. Br J Surg 
2005;92(4): 471-477.
9. Crippa S, Dominguez I, Rodriguez JR, Razo O, Thayer SP, Ryan DP, Warshaw AL, Fernandez-del Castillo 
C. Quality of life in pancreatic cancer: analysis by stage and treatment. J Gastrointest Surg 2008;12(5): 
783-793; discussion 793-784.
10. Kokoska ER, Stapleton DR, Virgo KS, Johnson FE, Wade TP. Quality of life measurements do not support 
palliative pancreatic cancer treatments. Int J Oncol 1998;13(6): 1323-1329.
11. Huang JJ, Yeo CJ, Sohn TA, Lillemoe KD, Sauter PK, Coleman J, Hruban RH, Cameron JL. Quality of life 
and outcomes after pancreaticoduodenectomy. Ann Surg 2000;231(6): 890-898.
12. A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil 
for locally unresectable pancreatic carcinoma. The Gastrointestinal Tumor Study Group. Ann Surg 
1979;189(2): 205-208.
13. Further evidence of effective adjuvant combined radiation and chemotherapy following curative 
resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 1987;59(12): 2006-2010.
14. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following 
curative resection. Arch Surg 1985;120(8): 899-903.
15. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, 
de Wit LT, Hennipman A, Wils J. Adjuvant radiotherapy and 5-fluorouracil after curative resection of 
cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract 
cancer cooperative group. Ann Surg 1999;230(6): 776-782; discussion 782-774.
16. Neoptolemos JP, Cunningham D, Friess H, Bassi C, Stocken DD, Tait DM, Dunn JA, Dervenis C, Lacaine 
F, Hickey H, Raraty MG, Ghaneh P, Buchler MW. Adjuvant therapy in pancreatic cancer: historical and 
current perspectives. Ann Oncol 2003;14(5): 675-692.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
54  |  Chapter 3
17. Smeenk HG, van Eijck CH, Hop WC, Erdmann J, Tran KC, Debois M, van Cutsem E, van Dekken H, 
Klinkenbijl JH, Jeekel J. Long-term survival and metastatic pattern of pancreatic and periampullary 
cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann 
Surg 2007;246(5): 734-740.
18. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis 
C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Buchler MW. A randomized trial of 
chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350(12): 
1200-1210.
19. Morak MJ, van der Gaast A, Incrocci L, van Dekken H, Hermans JJ, Jeekel J, Hop WC, Kazemier G, van 
Eijck CH. Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable 
pancreatic and periampullary cancer: a prospective randomized controlled trial. Ann Surg 2008;248(6): 
1031-1041.
20. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman 
SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a 
quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85(5): 
365-376.
21. Sloan J. Asking the obvious questions regarding patient burden. J Clin Oncol 2002;20(1): 4-6.
22. Slevin ML. Quality of life: philosophical question or clinical reality? Bmj 1992;305(6851): 466-469.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Quality of Life after CAI/RT vs Surgery Alone in Resectable Pancreatic and Periampullary Cancer  |  55
3
2014202 proefschrift Wouter Hogendoorn.indd   8 21-07-14   08:57
 
2014202 proefschrift Wouter Hogendoorn.indd   9 21-07-14   08:57
2014202 proefschrift Wouter Hogendoorn.indd   8 21-07-14   08:57
 
2014202 proefschrift Wouter Hogendoorn.indd   9 21-07-14   08:57
CHAPTER 4
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Improved survival by prevention of liver metastases 
in non-pancreatic cancers
J. Erdmann1, M.J.M. Morak1, H.J. Duivenvoorden2, H.van Dekken3, 
G. Kazemier1, N.F.M. Kok1, C.H.J. van Eijck1
1 Department of Surgery Erasmus MC, Rotterdam The Netherlands.
2 Methodologist-statistician, Erasmus MC, Rotterdam, The Netherlands.
3 Department of Pathology Erasmus MC, Rotterdam, The Netherlands.
Accepted HPB
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
58  |  Chapter 4
ABSTRACT
Background: In pursuit of improvement of survival after surgery for pancreatic cancer, several 
randomized trials have been conducted offering adjuvant chemotherapy with or without 
concomitant radiotherapy. For non-pancreatic periampullary cancers however, no proven adjuvant 
therapy is available.
Objective: To compare the effect on suvival of adjuvant intra-arterial chemotherapy with 
concomitant radiotherapy (CAI/RT) to surgery alone.
Methods: In 2008 we published the results of a randomized controlled trial comparing intra-
arterial chemotherapy with concomitant radiotherapy (CAI/RT) to observation. We now present 
the data after complete 5-year follow-up of all patients.
Results: Long-term survival (>60 months) was observed in 19 patients. CAI/RT did not influence 
survival for pancreatic cancer (20 vs 21 months p=0.9), For CAI/RT in non-pancreatic periampullary 
cancers, median survival was 37 vs 28 months and a doubling of the number of long-term 
survivors from 5 to 10 was seen. Interestingly, occurrence of livermetastases was also reduced by 
CAI/RT, from 57% to 29% (p=0.04). Cox regression revealed a substantial effect of CAI/RT on 
survival (hazard ratio 0.436, 95% CI: 0.231 to 0.825, p=0.01). The other independent factor was 
differentiation grade: p<0.01 (hazard ratio 2.548, 95% CI: 1.529 to 4.242).
Conclusions: This long term-analysis shows that for non-pancreatic periampullary cancers 
median and long-term survival is greatly improved after CAI/RT, probably because of the effective 
reduction of livermetastases. We advocate further investigation of this concept of CAI/RT.
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INTRODUCTION
The treatment of adenocarcinoma of the pancreas and periampullary region remains a challenge. 
Even for those few patients who are amenable to resection with curative intent overall survival 
remains poor. Most tumors arise in the pancreatic head near the ampulla of Vater. The majority 
of these tumors are of pancreatic ductal origin. Less frequently tumors in the pancreatic head 
region arise from the distal common bile duct, ampulla of Vater and duodenum, collectively and 
sometimes confusingly, known as periampullary cancers.1 Although histologically very similar, 
these tumors carry a more favorable prognosis. The classical hypothesis is that these tumors are 
diagnosed at an earlier stage because they lead to jaundice early due to their anatomical location. 
Another reason for early detection may be that some could be discovered at routine endoscopy. 
For these reasons non-pancreatic periampullary tumors may more frequently be amenable to 
surgical resection than their pancreatic counterparts. 
On the other hand non-pancreatic periampullary cancers may represent a separate family of 
tumors with a different biological behavior. This hypothesis is supported by the superior survival 
of periampullary cancers, even after having taken into account tumor size, positive lymph nodes 
and stage.2, 3
In pursuit of improvement of survival after surgery for pancreatic cancer, several randomized 
trials have been conducted offering adjuvant chemotherapy both with and without concomitant 
radiotherapy. This has recently led to the consensus that gemcitabine based adjuvant chemotherapy 
improves outcomes after surgery for pancreatic cancer. The role of adjuvant radiotherapy remains 
unclear.4 
On the other hand, the evidence that adjuvant chemotherapy is effective in patients with 
non-pancreatic periampullary cancers is limited. The first large trial was conducted offering a 
5-fluorouracil based regimen with concomitant radiotherapy, but there was no effect on survival.5 
Another, recent, report on gemcitabine based adjuvant therapy showed a small albeit significant 
improvement in survival after adjuvant chemotherapy.6
In 2008 we published the results of a randomized controlled trial comparing intra-arterial 
chemotherapy with concomitant radiotherapy (CAI/RT) to surgery alone.7 The groups were 
stratified for the location of the tumor (i.e. pancreatic or non-pancreatic periampullary),This 
study showed a prolonged time to progression after CAI/RT. For non-pancreatic periampullary 
tumors, CAI/RT induced a significant reduction in liver metastases. Median follow-up at the time 
of publication was 17 months. Since recurrence can be observed up to years after resection and 
only estimated survival could be calculated from this follow-up, we currently present the data 
after 5-year follow-up of all patients.
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METHODS
The study design was described in the primary analysis in detail7. Briefly, patients were randomized 
after resection into two groups: CAI/RT or no adjuvant therapy. All specimens were reviewed by 
one specialized pathologist (HvD), graded and staged according to UICC’s 2002 guidelines. Stage 
1A (T1N0) tumors of the ampullary region were excluded. Determination of tumor origin was 
based on micro- and macroscopic evaluation of the resected specimen. Duodenal, cystic and 
neuro-endocrine tumors were excluded. Other exclusion criteria were: age>75, karnofsky-Index 
=/< 50%, uncontrolled infection, previous chemo- or radiotherapy and aberrant vascular supply 
to the liver. Enrolled patients were prestratified for tumor origin (pancreatic or non-pancreatic 
periampullary adenocarcinoma). After recovery from surgery patients were randomized during 
their first visit to the outpatient clinic, according to a computer generated randomization list 
provided by the trial statistician. Treatment started within 6-12 weeks after surgery. Patients with 
complications resulting in a prolonged hospital stay were not randomized. During or before the 
first CAI and before RT, all patients were restaged by Computed Tomography (CT). Follow-up 
consisted of clinical and laboratory examinations every 3 months. During the first two years CT 
was performed every 3 months and every 6 months afterwards. Clinical signs of recurrence were 
indications for additional imaging. All patients were monitored to 5 years or up to death. All 
survival data was cross-checked with the national population registry.
Adjuvant treatment
The treatment schedule was described in full detail previously.7 Chemotherapy was administered 
through a catheter placed in the celiac trunk and left in place during the five treatment days of 
each cycle. Heparin was infused to prevent thrombosis. Cycles consisted of mitoxantrone on 
day one, followed by 5-fluorouracil/ folinic acid on days two to four and cisplatinum on day 
five. Toxicity was monitored and the dose was reduced 20% in case of toxicity >World Health 
Organization (WHO) degree II. After two weeks radiotherapy was started. A total of 54Gy was 
delivered in a single dose of 1.8 Gy five days a week. CAI was continued afterwards up to a total 
of six cycles with an interval of four weeks between each cycle. Therapy was discontinued in case 
of serious toxicity, WHO III/IV.
Statistics
Primary outcome was overall survival. Secondary endpoints were toxicity and disease-free survival. 
Initial power calculations led to a total of 120 patients in each group. The trial was approved by 
the local ethics committee. Inclusion was stopped because of gemcitabine based adjuvant therapy 
had become standard-care and an observation-only group was therefore considered unethical.
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Analyses were performed on an intention-to-treat basis. IBM SPSS Statistics version 20 for 
Windows was used for the current analyses. Significance was calculated using Chi-square for 
categorical and student-t for continuous variables. Statistical significance was defined at p=0.05 
(two-sided). All p-values were rounded to two decimals. Survival was estimated using the Kaplan 
Meier method, significance calculated by log-rank test.
In addition, significant factors from the univariate analysis were entered in a multivariate cox-
proportional hazards model. Hazard ratios are shown with 95% confidence interval (95% CI). 
Grade variables were considered of ordinal level and therefore coded as dummy variables.
RESULTS
Patients
From a cohort of 256 pancreatoduodenectomies, 120 patients were included in this trial. Fifty-
nine patients were randomized to the chemoradiation group and 61 to surgery alone. Baseline 
characteristics were not statistically significant different between groups except for differentiation 
grade (more poorly differentiated tumors in the CAI/RT group) and age (60 vs. 66 years).
TNM staging was not different between the groups; neither were presence of lymph nodes (60%) 
and radicality of resection (73-97%).
Median time from resection to start of CAI/RT was 61 days (range 42 to 96). Full 5-year follow-up 
was completed for all patients; one patient was lost to follow-up due to emigration.
Of the 59 patients assigned to CAI/RT, three patients refused treatment, three developed liver 
metastases as seen on the restaging CT-scan and one died waiting for the start of treatment. 
Therefore 52 patients received adjuvant treatment. Overall toxicity was mild, and led to 
discontinuation of CAI/RT in 13 patients, seven patients in the pancreatic cancer group and six 
in the non-pancreatic periampullary group). Thirty-six percent of all patients received the full six 
cycles of CAI/RT: Six in the pancreatic cancer group and 15 in the non-pancreatic periampullary 
group. The median number of cycles administered was three in the pancreatic cancer group and 
six in the non-pancreatic periampullary group.
Overall Survival
The primary analysis was based on 82 deaths. Longer follow-up led to registration of 18 more 
events. Therefore survival analysis was based on 100 deaths. Long-term survival (defined as 
>60 months) was observed in 19 patients (Figure 1). Overall survival for patients suffering from 
pancreatic cancer is worse than survival for patients suffering from non-pancreatic periampullary 
cancer, regardless of therapy (median survival 20 vs. 32 months, p<0.01). For the whole study 
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group CAI/RT did not improve survival (primary endpoint, Figure 1). CAI/RT did not influence 
survival for pancreatic cancer (20 vs. 21 months p= 0.87 Cox-regression). However, for the stratum 
non-pancreatic periampullary cancer the number of long-term survivors in the CAI/RT group was 
twofold the number of long-term survivors after surgery alone (5 vs. 10). Overall survival was 
also superior after CAI/RT, with a median actual survival of 37 vs. 28 months (Figure 2).The log 
rank test approached statistical significance (P=0.08). Furthermore, Cox regression revealed a 
substantial effect of CAI/RT on survival (hazard ratio 0.44, 95% CI: 0.23 to 0.83, p=0.01).The 
other independent factor in the same regression model was differentiation grade (p<0.01 hazard 
ratio 2.55, 95% CI: 1.53 to 4.24). Factors were tested for their independent contribution in the 
model. Kaplan-Meier analysis of well, moderate and poorly differentiated carcinomas showed 
that well differentiated non-pancreatic periampullary cancers did not benefit from CAI/RT (median 
survival 54 months after surgery only vs. 44 months with CAI/RT, p=0.38). When only moderate/
poor differentiated tumors are included in the Kaplan Meier analyses, significant improvement of 
survival after CAI/RT is found (median 22 vs. 36 months, p<0.01 log-rank). 1
Months 0 10 20 30 40 50 60
CAI/RT 59 48 30 24 18 15 13
Surgery only 61 50 27 17 12 9 6
Figure 1:  Kaplan Meier, overall survival CAI/RT (dotted line) vs Surgery alone, P= 0.163 log-rank.
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2
Months 0 10 20 30 40 50 60
CAI/RT 28 27 20 17 13 12 10
Surgery only 30 23 17 12 8 7 5
Figure 2:  Kaplan Meier, overall survival, non-pancreatic periampullary cancer: CAI/RT (dotted line) 
vs Surgery only, p = 0.08 log-rank, hazard ratio 0.436, 95% CI: 0.231 to 0.825, p=0.01.
Disease free survival
Time to progression was longer for patients treated by CAI/RT for the whole study group, (13 vs. 
8 months p=0.03, Figure 3). There was no significant effect of CAI/RT on time to progression in 
pancreatic cancer (12 vs. 8 months, p=0.21 log-rank, cox-regression p=0.24). For non-pancreatic 
periampullary cancer prolonged time to progression was assessed for the CAI/RT group (Figure 
4, 19 vs. 8months, P=0.10 log-rank, Hazard ratio for recurrent disease 0.48 95% CI: 0.25 to 
0.90 p= 0.02). Again, when well-differentiated cancers were excluded, log-rank test of Kaplan-
Meier became significant (p=0.01). Recurrences were observed in 93 patients. The recurrence 
pattern is shown in Table 1. Interestingly, occurrence of liver metastases in patients with non-
pancreatic periampullary cancer was identical to the primary analysis; CAI/RT effectively reduced 
the occurrence from 17 to 8 cases (p = 0.04 Chi-square, hazard ratio 3.27 95% CI: 1.10 to 9.80), 
no effect could be shown in time to occurrence of these liver metastasis.
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3
Months 0 10 20 30 40 50 60
CAI/RT 59 36 19 17 13 13 13
Surgery only 61 27 12 10 7 6 6
Figure 3:   Kaplan Meier, disease-free survival, CAI/RT (dotted line) vs Surgery only, p = 0.04.
Table 1. Recurrence pattern, PC: pancreatic cancer, NPAC: non-pancreatic periampullary cancer. 
Recurrence pattern PC     NPAC    
  CAI/RT % Control %  P CAI/RT % Control % P 
N 31   31     28   30    
First Recurrence                  
Local 14 45% 19 61% 0.30 11 39% 9 30% 0.60
Liver 14 45% 11 35% 0.60 7 25% 13 43% 0.17
Local and Liver 6 19% 4 13% 0.73 2 7% 3 10% 1.00
Lung 5 16% 3 10% 0.71 3 11% 3 10% 1.00
Other 0 0% 6 19% 0.03 3 11% 3 10% 1.00
Cumulative Recurrence                    
Local 15 48% 22 71% 0.12 13 46% 12 40% 0.79
Liver 15 48% 16 52% 1.00 8 29% 17 57% 0.04
Local and Liver 7 23% 11 35% 0.26 4 14% 7 23% 0.51
Lung 5 16% 3 10% 0.71 3 11% 5 17% 0.71
Other 1 3% 9 29% 0.01 5 18% 5 17% 1.00
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4
Months 0 10 20 30 40 50 60
CAI/RT 28 21 13 12 10 10 10
Surgery only 30 14 8 8 6 5 5
Figure 4:  Disease-free survival, non-pancreatic periampullary cancer, Kaplan Meier, CAI/RT (dotted 
line) vs. Surgery only, (19 vs. 8months, P = 0.10 log-rank, Hazard ratio for recurrent 
disease 0.48 95% CI: 0.25 to 0.90 p = 0.02).
DISCUSSION
For pancreatic cancer there appears to be no survival benefit for adjuvant CAI/RT and gemcitabine-
based regimens have proven their effectivity.6 The effect of CAI/RT in this group is disappointing and 
confirms that true pancreatic cancer has a dismal prognosis despite the addition of chemotherapy 
and radiotherapy. However, for non-pancreatic periampullary cancer, adjuvant CAI/RT improves 
overall survival and disease-free survival. This is remarkable and therefore we would like to draw 
attention to the benefit of the aforementioned adjuvant regimen in the latter group.
The evidence in the literature for multimodality treatment of non-pancreatic periampullary tumors 
is sparse. The first large randomized controlled trial to investigate non-pancreatic periampullary 
cancers was published by Klinkenbijl et al. in 1999.5 Long-term follow-up was published in 2007.8 
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In this EORTC trial adjuvant 5-fluorouracil based chemotherapy with concomitant radiotherapy 
(40Gy) was compared to observation. No significant differences were found regarding survival. 
Liver metastases occurred in 50 % of the patients. There were no significant differences in 
occurrence of these liver metastases between treatment groups. Recently, the ESPAC-3 trial for 
periampullary cancer was published.6 This trial compared three study groups; 5-fluorouracil based 
chemotherapy, gemcitabine based chemotherapy and observation only. In analysis of the primary 
endpoint, significance with regard to overall survival was not observed. After taking into account 
other variables (i.e. differentiation grade) in secondary analyses they demonstrated a beneficial 
effect for adjuvant chemotherapy (hazard ratio 0.75, 95% CI: 0.57 to 0.98 p= 0.03). This effect 
was smaller than the effect of CAI/RT as observed in the current study.
The rationale for CAI/RT in the present study was twofold: reduction of liver metastases by CAI 
and improved local control by RT. And indeed, for non-pancreatic periampullary cancers CAI/
RT led to reduction of occurrence of liver metastases and a significant effect was observed on 
median survival, disease-free survival and also more long-term survivors (5 patients in observation 
group vs. 10 in CAI/RT). We could not show a significant effect on local recurrence. The EORTC 
study also included RT, 40Gy compared to the 54Gy in the present study. Bearing in mind the 
effects of RT in the ESPAC-1 trial9 where it was even detrimental for survival, it is more likely that 
CAI is responsible for fewer liver metastases and consequent effect on survival and not RT. This 
strengthens the conclusions of both the EORTC5 and ESPAC-19 trials that the role for adjuvant RT 
in the prevention of local recurrence of (non-)pancreatic periampullary cancers is doubtful.
Two phase II clinical trials and a case study preceded this trial.10-12 Both trials showed a decrease 
in liver metastases and improved survival after CAI. The rationale is that by infusing selectively, 
a much higher dose can be achieved in the target organ, in this case the liver. We could not 
confirm these results for pancreatic cancers, but a clear effect was observed in the non-pancreatic 
periampullary cancer group. It is not precluded that for pancreatic cancers, the mitoxantrone, 
5-flourouracil and cisplatinum combination used in this study may be inferior to a gemcitabine 
based regimen. Furthermore, recent developments of new therapeutic agents and combination 
therapy have led to more effective systemic therapy in metastatic pancreatic cancer using a 
5-fluorouracil, leucovorin, irinotecan en oxaliplatin (Folfirinox) regimen.13 We speculate that a 
different agent or combination could be effective as CAI in pancreatic cancers.
In the Cox regression analysis we showed that both differentiation grade and adjuvant treatment 
were of independent influence on overall and disease-free survival. Differentiation grade was 
inversely correlated with survival, which is concordant with other studies.6, 8 Since survival 
after resection of well differentiated cancers is already much better than for moderately/poorly 
differentiated tumors, the effect of adjuvant therapy may be concealed. In our study we found 
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no significant difference between treatment and observation for these patients (54 vs 44 months 
median survival, p=0.38). When we corrected for this effect in the multivariate analysis, the 
treatment effect proved to be significant. Also the survival benefit for moderate and poorly 
differentiated tumors proved to be larger after CAI/RT compared to observation (median 36 vs. 
22 months, p<0.01 log-rank).
This long term analysis shows interesting effects of adjuvant CAI/RT on survival in patients with 
non-pancreatic periampullary cancer that were not revealed in the primary analysis. Strengths 
of this study include its randomized design with prestratification by tumor origin. We presented 
follow-up of all patients to at least 5 years or to death. However, we admit the weaknesses of the 
study. First, the observational group did not receive adjuvant treatment, which is standard care 
nowadays. When we initiated this trial, studies like the ESPAC-1 or CONKO-1 were not published 
yet. We included radiotherapy as part of the protocol because we expected to be able to reduce 
local relapse. Analysis of our results reveals that, although some effect can be seen in patients with 
pancreatic cancer, there is no significant effect of radiotherapy on local recurrence rates. Second, 
the early break-up of the study led to groups which were twofold smaller than originally planned 
and thus a type two statistical error could occur in the pancreatic cancer group. Nevertheless, we 
addressed a significant and substantial effect of CAI/RT in non-pancreatic periampullary tumors 
in this relatively small group. Furthermore, one could argue that the majority of patients did not 
receive all planned cycles of CAI. We acknowledge this, but would like to stress that for most 
patients it was because of early progression of the disease. The timing of randomization after 
recovery from surgery may be debated. Ideally, further randomized studies on adjuvant therapies 
in patients with either pancreatic cancer or non-pancreatic periampullary cancer would rather 
assign patients to either treatment before surgery. Probably a significant number of patients 
would drop out of the study because of irresectability, postoperative morbidity and mortality 
and withdrawal. Finally, one could argue that the proposed schedule of CAI/RT is intense and 
would interfere with quality of life during the short time most of the patients live after “curative” 
resection. We previously published that quality of life14 was not adversely affected by this adjuvant 
regimen and toxicity was relatively mild.7
In the current study we deliberately differentiate between pancreatic and non-pancreatic 
periampullary cancers. Interestingly, “periampullary” cancers were only intentionally included in 
three other randomised trials.5, 6, 15 As was also clearly described in the recent paper by Verbeke et 
al1, 16, correct classification of periampullary cancers can be difficult for inexperienced pathologists. 
Especially large multicenter studies without central pathology control are at risk of falsely including 
non-pancreatic tumors in a pancreatic cancer study group and vice versa. When considering the 
difference in effect on survival by CAI/RT between pancreatic and non-pancreatic periampullary 
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cancers in our study, it is clear that correct differentiation between these two groups is essential 
for the interpretation of effects of adjuvant therapy in randomized trials.
In conclusion, patients with resectable non-pancreatic periampullary cancer may benefit from 
adjuvant CAI/RT as it significantly prolongs overall and disease-free survival, probably because of 
the effective reduction of liver metastasis. Further trials should clearly distinguish non-pancreatic 
periampullary cancer from pancreatic cancer. In the past, the differences between these two 
cancers had impact only on prognosis. Now, it may guide clinical management. 
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ABSTRACT
Aim: To address the role of a dedicated radiologist and high quality CT scanning in staging of 
patients referred with suspected locally advanced pancreatic cancer. Furthermore, the value of 
laparoscopy in detecting CT occult metastases in these patients was assessed.
Methods: In a prospective cohort study, 116 patients with suspected unresectable pancreatic 
cancer referred from peripheral hospitals (107) or our own gastroenterology department (9) were 
analysed. CT scans from referral centres were reviewed and in case of locally advanced disease or 
uncertain metastatic disease, patients underwent a laparoscopy to detect CT occult metastases. 
Patients without metastases were offered 5-FU based chemoradiotherapy.
Results: After reviewing 107 abdominal CT scans from referral centres, 73 (68%) scans had to 
be repeated due to unacceptable quality. Locally advanced disease was confirmed in 59 (55%) 
patients and metastatic disease was found in 24 patients (22%). During laparoscopy, metastases 
were found in 24/ 68 (35%) patients with locally advanced disease on CT scan and metastases 
were confirmed in 3/5 (60%) with suspected metastases.  
Overall, only 46/ 116 (40%) patients with suspected unresectable disease appeared to have 
locally advanced pancreatic cancer after adequate staging including laparoscopy in our centre.
Conclusion: Correct staging is difficult in patients with suspected locally advanced pancreatic 
cancer and should preferably be performed in centres with technically advanced equipment and 
experienced radiologists. Laparoscopy should be offered to patients before locoregional therapy.
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INTRODUCTION
Pancreatic carcinoma is the 4th most common cause of cancer related death worldwide.1 Despite 
improved quality of surgery, the prognosis of patients with pancreatic cancer is still dismal. 
Additional treatment seems essential to improve outcome in these patients. Several studies have 
shown benefit for neoadjuvant or adjuvant treatment in patients with resectable pancreatic 
cancer.2-4 In contrast, 80-90% of patients suffer from either unresectable or metastatic disease at 
the time of diagnosis. In these patients, no curation can be established and survival relies on the 
effectiveness of palliative chemotherapy and/ or radiation. 
The introduction of spiral or helical computed tomography (CT) scanning has greatly affected 
the selection of patients eligible for surgical exploration, thus increasing overall resectability rates 
in these patients. Vascular tumour ingrowth for example, can be visualised with pre-operative 
helical scanning with high accuracy.5 However, small metastatic lesions can be missed.6-8 
Laparoscopy has proven to be able to detect these metastases that mainly consist of peritoneal 
and superficial liver lesions. As a result several groups recommend diagnostic laparoscopy in 
combination with or without laparoscopic ultrasonography as a standard procedure in the staging 
of all patients with resectable as well as unresectable pancreatic cancer.9,10 However recent studies 
using high quality CT-scanning in resectable pancreatic cancer patients revealed that only a small 
percentage of these patients would benefit from a routine diagnostic laparoscopy.11,12 Nieveen 
et al. found a 13% detection rate of metastatic disease during laparoscopy in a group of 297 
consecutive patients with resectable disease. The low detection rate and subsequent need for, 
and excellent long term results of, bypass surgery validate the conclusion that general use of 
diagnostic laparoscopy in all pancreatic cancer patients is not cost-effective and not justified.12 
Tilleman et al. concluded that there is no indication to perform a routine laparoscopy in patients 
with resectable pancreatic cancer, but that there might be an indication in a, non-specified, well-
defined high-risk subgroup.11 
Patients with locally advanced disease in the work-up, are known to have this higher incidence of 
CT-occult liver and peritoneal metastases13 and laparoscopy has been reported to be of additional 
value to improve assessment of tumour stage in these patients with metastatic detection rates 
varying between 34-37%.6,14,15
Because a laparoscopy appears most valuable in patients with locally unresectable but not in 
resectable disease, cautious staging based on CT scanning is of utmost importance. However, 
patients with pancreatic cancer often present in non-specialised centres without high quality CT 
scans or specific pancreatic imaging protocols. After referral to specialised centres, the quality of 
the CT scans has to be assessed and designated radiologists review appropriate scans. New scans 
are made in case of poor quality. 
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Several studies imply that chemotherapy should be offered to patients with locally advanced 
pancreatic cancer as in metastatic disease because of disappointing results of chemoradiotherapy. 
However, laparoscopy was no part of the staging regime in these studies resulting in the inclusion 
of metastasised disease and thus, considering the fact that chemoradiotherapy only has an 
effect on localised disease, an underestimation of the effect of chemoradiotherapy.16-18 Based 
on previous results in our centre, chemoradiotherapy is a promising option in patients with 
unresectable, non-metastasised pancreatic cancer based on laparoscopy.19
The aim of this study was to address the role of a dedicated radiologist and high quality CT 
scanning in staging of patients referred with suspected locally advanced pancreatic cancer. 
Furthermore, the value of laparoscopy in detecting CT occult metastases in these patients was 
assessed. 
METHODS
In this study we evaluated all patients referred to the surgical department of the Erasmus 
Medical Centre (Erasmus MC) between January 1995 and March 2007 with the diagnosis 
of locally advanced pancreatic cancer based on abdominal CT scan. In most patients with 
obstructive jaundice, preoperative biliary drainage was performed by endoscopic retrograde 
cholangiopancreatography (ERCP) and placement of an endoprosthesis; others received either a 
papillotomy or percutaneous transhepatic drainage. 
Abdominal CT Scan 
From 1995- 1999 CT scanning in the Erasmus MC was performed using a Siemens Somatom Plus 
single slice CT (Siemens Medical Solutions; Erlangen, Germany). After 1999 a Siemens multislice 
spiral CT scanner was used (Siemens Medical Solutions; Erlangen, Germany). 
Our standard triphasic pancreatic protocol consists of a non contrast enhanced scan with a slice 
thickness of 5.0 mm, an arterial/ pancreatic phase at 40 seconds after the initiation of contrast 
injection (Visipaque 320 mg/ml) with a slice thickness of 3.0 mm, followed by 5.0-mm-thick slices 
at 80 seconds (portal venous phase). One hundred fifty milliliters of contrast material is injected 
intravenously at a rate of 3.5 ml/ sec. 
One of our designated radiologists (Hermans) reviewed all abdominal CT scans. CT scans from 
peripheral hospitals were judged as of sufficient quality in case of triphasic scanning, a comparable 
scanning protocol, a maximum slice thickness of 3.0 mm in arterial/ pancreatic phase and 5.0 mm 
in portal venous phase and no movement artefacts. 
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A pancreatic tumour was classified as resectable, uncertain resectable, unresectable, suspected 
metastatic or metastatic, based on CT scan. In case of metastatic disease, the resectability of the 
primary tumour was not addressed and could be either resectable or unresectable. All metastatic 
lesions were histopathologically proven.
In case of (uncertain) resectable disease, a laparotomy was performed outside the perspectives 
of this study. All patients with unresectable disease and uncertain metastatic disease underwent 
a laparoscopy.
Unresectable disease was described by Loyer and Phoa defined as: i) infiltration of peripancreatic 
fatplanes, the hepatoduodenal ligament and the mesentery (Figure 1), ii) >180º encasement of 
the portal or superior mesenteric vein or of the hepatic or superior mesenteric artery (Figure 1), 
iii) infiltration of the vessel, i.e. ingrowth or thrombosis (Figure 2).20,21 
Figure 1: Infiltration of the peripancreatic fatplane and 180º encasement of the superior mesenteric artery 
(white) by tumour (grey).
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Figure 2: Thrombus (grey) located in the portal vein (white).
Diagnostic Laparoscopy
Patients undergo examination under general anaesthesia as outpatients or with a 24-hour 
observation stay. Following establishment of pneumoperitoneum, a 10 mm trocar is inserted 
through an infraumbilical incision. The laparoscope is introduced through this trocar, and 
examination begins by inspection of the lower abdomen and pelvis. The laparoscope is then 
rotated for examination of the upper quadrants. Inspection begins by assessment of the 
omentum and subdiaphragmatic spaces. Meticulous examination of the liver surface is essential. 
Insertion of a second and third 5-mm trocar in the right upper quadrant is necessary for adequate 
evaluation of the posterior aspect of the liver and biopsies of suspected lesions. Elevation of the 
transverse colon and inspection of the mesentery and Treitz’ ligament is performed with the 
patient placed in anti- Trendelenburg position. Finally biopsies of suspected lesions are taken 
with biopsy forceps (superficial lesions) or with Rotex or Tru-cut needles (deeper lesions) under 
guidance of the laparoscope. We do not perform extensive dissection of the retrogastric space 
and lesser sac routinely, nor peritoneal lavage. Laparoscopic ultrasound was not used routinely. 
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Treatment
If no metastases were found during laparoscopy, a percutaneous or endoscopic ultrasound fine 
needle aspiration of the primary tumour was performed to confirm malignancy. 
All patients with true (laparoscopy based, histopathologically proven) locally advanced, i.e. 
non metastasised, pancreatic cancer were offered chemoradiotherapy consisting of 5-FU in 
combination with radiotherapy. 
Patients with metastatic disease based on laparoscopy were offered chemotherapy. 
Statistics
Analysis was done with the Statistical Package for the Social Sciences version 11.5 (SPSS). Survival 
curves were computed according to the Kaplan Meier method and comparison of survival curves 
was done with the log-rank test.
RESULTS
From January 1995 until March 2007 116 consecutive patients referred with the presumed 
diagnosis of locally advanced pancreatic tumours according to CT scan were incorporated in this 
prospective cohort study. The median age in these patients was 63 years (range 43-92 years), 
and 68 of the patients were men. Presenting symptoms were weight loss (n=94), pain (n=87), 
obstructive jaundice (n=68) and diabetes mellitus de novo (n=13). Ca 19.9 was elevated (>34kU/l) 
in 102 patients, whereas CEA was elevated (>4.99µg/l) in 56 patients. Tumour size was larger 
than 3 cm radiologically in 95 patients. 
CT Scan
Of the 116 patients, 107 patients were referred from peripheral hospitals, while 9 patients 
were referred from our own gastroenterology department. CT scans of seventy-three (68%) of 
the 107 referred patients had to be repeated while the other scans were of predefined quality. 
Unresectable disease was found in 59 patients and uncertain metastatic disease in 5 patients. 
Furthermore, resectable disease was found in 6 patients, uncertain unresectable disease in 13 
patients and metastatic disease in 24 patients. 
The cause of unresectability in all 68 (59 plus the nine patients from our own gastroenterology 
department) patients is shown in Table I. 
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Table I: CT criteria for unresectability (n=68)
Infiltration of peripancreatic fatplanes, HDL +/- mesentery N=1
>180º encasement of the PV, SMV, HA or SMA N=38
Infiltration of the vessel (i.e. ingrowth or thrombosis) N=16
Combination of encasement and infiltration of the vessel N=13
HDL= hepatoduodenal ligament, PV= portal vein, SMV= superior mesenteric vein, HA= hepatic artery, SMA= 
superior mesenteric artery.
Diagnostic Laparoscopy
The mean amount of days between CT scan and laparoscopy was 13 (range 0- 49 days, SD ±10). 
The median operative time, including anaesthesia, was 79 minutes (range 41- 130 min). In two 
patients there was an indication for a consecutive laparoscopic gastroenterostomy. 
Twenty-four (35%) of the 68 patients with unresectable disease appeared to have metastatic 
disease at laparoscopy. Metastases were mainly located on the liver and peritoneum (Table II). No 
correlation could be found between the reason for unresectability (i.e. ingrowth into peripancreatic 
fatplane, into adjacent vessels or encasement of these vessels) on CT scan and the presence of 
metastases at laparoscopy. There was no difference in detection rate between CT scans performed 
before 1999 (6/16= 27%) and CT scans performed in/or after 1999 (18/28=39%). All metastases 
were proven histopathologically.
Table II: Laparoscopic findings
No signs of metastases on laparoscopy N=44 (65%)
Metastases:  N=24 (35%)
            liver      N= 5  (21%)
            peritoneum/ ascites      N=14 (58%)
            lymph nodes near celiac trunk      N= 3  (13%)
            liver and peritoneum      N= 2  ( 8%)
There were 2 major complications in the entire group: In one patient the laparoscopic 
gastroenterostomy was insufficient for which a relaparotomy was necessary and in another 
patient a prolonged paralytic ileus was seen after laparoscopy. The mean overall hospital stay was 
5 days (range 1- 50 days).
Of the 5 patients with suspected metastatic lesions based on CT scan, all lesions were located in 
the liver. Laparoscopy confirmed these metastases in only three of the patients. 
After laparoscopy 44 (65%) of the 68 patients with locally advanced pancreatic cancer on 
abdominal CT scan were diagnosed with true, non-metastatic, locally advanced disease and two 
(40%) out of five patients with uncertain metastatic disease. A percutaneous biopsy or fine needle 
aspiration during subsequent endoscopic ultrasound confirmed malignancy in all these patients. 
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In conclusion, after reviewing abdominal CT scan and laparoscopy in all 116 patients with 
suspected unresectable disease at referral, 46/ 116 patients (40%) appeared to have non-
metastatic unresectable pancreatic cancer and chemoradiotherapy was offered to all these 
patients.
DISCUSSION
Because the complexity of pancreatic cancer, the different stages it presents in, the need for exact 
imaging, the difficulty of surgery and the ever changing non-surgical or adjuvant treatments, it 
remains a disease best treated in specialised centres. Although for diagnosing pancreatic cancer 
abdominal CT scan remains an important imaging module, the quality of scans performed in non-
specialised centres remains poor and a high quality pancreatic cancer specified protocol CT scan 
needs to be performed to be able to draw conclusions concerning resectability and the presence 
of metastases. On the other hand radiologists need to be trained to be able to address pancreatic 
cancer specific issues, as there are vascular invasion and or encasement. This is based on our 
results where CT scans had to be repeated in our institution in 68% of the patients and only 55% 
of the patients referred for unresectable disease based on CT scan, did have an unresectable 
pancreatic tumour after reviewing. And even our staging methods and radiologist’s experience 
are not flawless. Although we diagnosed locally advanced disease on abdominal CT scan and 
laparoscopy in 46 patients (i.e. only 40% of the originally referred patients), a laparotomy and 
thoracic CT scan revealed metastases in six more patients. Because a thoracic CT scan is less 
invasive than a laparoscopy, a thoracic CT scan before laparoscopy should be considered in future 
studies on unresectable pancreatic cancer. 
Literature
In this second largest group of patients reported in literature with locally advanced pancreatic 
cancer that underwent a laparoscopy we can confirm the 37% detection rate of CT occult 
metastases found by Shoup et al.14 However, where they used a single site for the laparoscope 
and only inserted a 5-mm trocar in case of suspected metastatic disease, we routinely inserted 
a second and third 5-mm trocar in the right upper quadrant for adequate evaluation of the 
posterior aspect of the liver. Consequently, the 37% detection rate after laparoscopy mentioned 
by Shoup et al. might even be an underestimation. One smaller study performed by Liu found 
similar results (34% detection rate), but metastases were mainly found through peritoneal lavage 
cytology during laparoscopy.6 We did not perform peritoneal lavage cytology. A combination of 
standard laparoscopy and peritoneal lavage might have led to an even higher detection rate. 
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Locally advanced vs. metastatic disease 
In our opinion it is important to discriminate between locally advanced and metastatic disease 
because of the implications for further treatment. In the past, locally advanced and metastatic 
pancreatic cancer was described as one disease entity, i.e. advanced pancreatic cancer, and was 
consequently treated identical. In this combined group, chemotherapy containing gemcitabine is 
the better treatment option although, as far as we know, randomised controlled trials containing 
radiotherapy have not been performed.22-24 
Locally advanced and metastatic disease should be considered as two different entities. 
Where the optimal treatment, i.e. chemotherapy or chemoradiotherapy, is still disputable 
in locally advanced cancer, chemotherapy is the only option for patients with metastasised 
disease. Overall survival figures in locally advanced disease vary between 11- 14 months after 
chemotherapy25,26 and between 7- 15 months after chemoradiotherapy depending on the used 
chemotherapeutics.16,17,19,26 In metastatic disease, median survival figures vary between 8- 11 
months.
The staging however, remains inadequate because these studies are based on CT imaging only, 
consequently incorporating metastatic disease in over a third of the included patients. This 
resulted in underestimating the effect of locoregional therapy, i.e. chemoradiotherapy, in favour 
of systemic therapy, which proved to be effective in metastatic disease. 
In two studies, patients with locally advanced pancreatic cancer were adequately staged.27,28 Both 
studies addressed the effect of chemoradiation either in combination with 5-FU and mitomycin-C 
or with gemcitabine and irinotecan. Cohen et al. reported a median survival of 8.4 vs. 7.1 
months after radiotherapy with 5-FU and mitomycin-C compared to radiotherapy alone. Mishra 
et al. preliminary stopped their study after accruing 20 patients because of disappointing results 
(median survival of 8.8 months). However both studies used a laparotomy as staging module: 
Cohen staged all patients with laparotomy and Mishra staged at least part of his patients with 
laparotomy. Their poor results might be explained by the fact that major operative trauma may 
favour the development of tumour recurrence. An invasiveness dependent association between 
surgical trauma and tumour recurrence has been supported by previous in vivo and in vitro 
studies, showing less metastases after laparoscopy compared to laparotomy.29,30 In our study all 
patients were staged by laparoscopy, resulting in less surgical stress and indeed a better median 
overall survival (11.7 months). 
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Conclusion
In conclusion we think that adequate staging should be performed in a specialised centre because 
of the considerable percentage of incorrectly staged patients referred from peripheral centres. 
Our study shows that after reviewing CT scans and laparoscopy in patients with suspected locally 
advanced pancreatic cancer, only 40% of these patients appeared to have true unresectable, 
non-metastasised pancreatic cancer. Only after careful staging including laparoscopy, results of 
future studies on either locoregional therapy or systemic therapy for locally advanced pancreatic 
cancer can be interpreted correctly. 
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ABSTRACT
Background and Purpose: To investigate the efficacy and toxicity of a short intensive Uracil/
Tegafur (UFT) based chemoradiotherapy scheme combined with Celecoxib in locally advanced 
pancreatic cancer.
Material and Methods: The Academic Medical Centre, Amsterdam and the Erasmus Medical 
Centre, Rotterdam enrolled eighty-three eligible patients with unresectable pancreatic cancer in 
a prospective multicentre phase II study. Median age was 62 years, median tumour size 40 mm 
and the majority of the patients (85%) had pancreatic head cancers. Treatment consisted of 20 x 
2.5 Gy radiotherapy combined with UFT 300 mg/m2 per day, Leucovorin (folinic acid) 30 mg and 
Celecoxib 800 mg for 28 days concomitant with radiotherapy. Four patients were lost to follow-
up. 
Results: Full treatment compliance was achieved 55% of patients, 80% received at least three 
weeks of treatment. No partial or complete response was observed. Median survival was 10.6 
months and median time to progression 6.9 months. Toxicity was substantial with 28% grade 
III-IV gastrointestinal toxicity and two early toxic deaths.
Conclusions: Based on the lack of response, the substantial toxicity of mainly gastro-intestinal 
origin and the reported mediocre overall and progression free survival, we can not advise our 
short intensive chemoradiotherapy schedule as standard treatment. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
UFT/ Leucovorin/ Celecoxib Combined with RT in Locally Advanced Pancreatic cancer  |  89
6
INTRODUCTION
Pancreatic carcinoma is the 4th most common cause of cancer related death worldwide, with an 
overall 5 year survival rate of < 5%.1 At presentation, only 10-20% of patients have resectable 
disease, half of the remaining patients has already distant metastases and the other half has 
locally advanced disease not amenable for a curative resection.2 
Since the publication of the Gastro Intestinal Tumour Study Group (GITSG) in 19813, patients 
with locally advanced pancreatic cancer are treated with radiotherapy in combination with 5 
fluorouracil (5-FU). In a number of studies 5-FU has been replaced by gemcitabine in the 
treatment of unresectable pancreatic cancer, either alone, in combination with radiotherapy or 
in combination with other drugs. However, at the start of this study, no clear benefit of either 
treatment had been established.4-6 
In the Academic Medical Centre in Amsterdam and the Erasmus Medical Centre Rotterdam, 
various studies have been performed to improve the results of radiotherapy or 5-FU based 
chemoradiotherapy in patients with unresectable pancreatic cancer.7, 8-11 So far, most studies 
showed similar results with a median overall survival between 8 and 11 months. Studies in 
metastatic colorectal cancer have demonstrated that oral Uracil/ Tegafur (UFT) combined with 
leucovorin has an equivalent efficacy as intravenous 5-FU with leucovorin, but is safer and more 
convenient.12, 13 In a phase I trial in patients with locally advanced and metastatic pancreatic 
cancer, UFT combined with leucovorin and radiotherapy was feasible, with the obvious benefit 
of an oral treatment.14 
In animal models, selective inhibition of cyclooxygenase-2 (COX-2) activity is associated with 
enhanced radiation sensitivity of tumours without enhancement of the damage to normal 
tissue.15 Pancreatic cancers overexpress COX-2 of in 31- 90 % of the tumours. Theoratically COX-
2 inhibitors could therefore enhance the effect of radiotherapy.15, 16
In the present study we investigated the safety and efficacy of a short intensive course of 
radiotherapy (50 Gy in 4 weeks) with UFT, leucovorin and celecoxib in patients with pathologically 
proven locally advanced pancreatic cancer.  
 
METHODS
Patients
Eligibility criteria included a cytologically or histologically confirmed unresectable tumour of the 
pancreas, smaller than 7x7x7 cm and without metastatic disease. Further inclusion criteria were 
an adequate hematologic parameters (leucocytes > 3.0x109/l, platelets > 100x109/l, haemoglobin 
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> 5.6 mmol/l), renal function (creatinine < 135 mmol/l) and liver function (total serum bilirubin < 
2 mg/dl, partial thromboplastin time > 60%), age > 18 years and ECOG performance status ≤ 2.
Patients with prior radiotherapy or chemotherapy, lymph node metastases outside the radiation 
target volume, hypersensitivity to celecoxib or other COX-2 inhibitors or serious bleeding 
disorders were excluded as well as patients with previous or current malignancies at other sites, 
no effective contraception and child- bearing or breast-feeding women. All patients signed an 
informed consent before inclusion.
Resectability was assessed by CT scan or at explorative laparotomy. Unresectable disease 
determined by triphasic contrast enhanced helical CT-scan was based on criteria defined by Loyer 
and Phoa as: i) infiltration of peripancreatic fatplanes, the hepatoduodenal ligament and the 
mesentery, ii) >180º encasement of the portal or superior mesenteric vein or of the hepatic or 
superior mesenteric artery, iii) infiltration of the vessel, i.e. ingrowth or thrombosis.17, 18 
During treatment patients were weekly monitored for toxicity or signs of early disease progression. 
After treatment, patients were followed up with clinical and laboratory examinations and CT 
scans every three months during the first two years and every six months thereafter. Clinical signs 
of recurrence were indications for additional examinations. 
Toxicity was scored according to the National Cancer Institute (NCI) Common Toxicity Criteria, 
Version 2.19 Tumour response was measured according to RECIST as complete response (CR), 
partial response (PR), stable disease (SD) or progressive disease (PD).20 
Treatment
Radiotherapy was delivered according to the guidelines of the International Commission on 
Radiation Units and Measurements (ICRU) report 50 using a linear accelerator with photon beams 
of at least 6MV energy. The Clinical Target Volume (CTV) consisted of the macroscopically visible 
tumour on CT scan plus assumed microscopic extension. The Planning Target Volume (PTV) was 
defined as the CTV plus 15 mm margin in cranial and caudal direction and 10 mm in all other 
directions. Typically the PTV volume varied between 250 and 350 cubic centimetre (cc). A total 
dose (TD) of 50 Gray (Gy) was delivered in 20 fractions of 2.5 Gy, five days a week in four weeks 
using a three dimensional conformal technique with a minimum of three, usually 5-7, beams. The 
minimum and maximum doses in the PTV were not allowed to exceed 5% of the planned dose. 
Organs at risk were the spinal cord, kidneys, liver and small bowel. The maximum allowed dose to 
any part of the spinal cord was an equivalent dose of 46 Gy/23 fractions, the maximum allowed 
dose to one whole kidney was 25 Gy. Part of one kidney was allowed a higher dose provided the 
other (functioning) kidney was spared. The entire liver was allowed a maximum dose of 30 Gy 
and the small bowel, except for a small part of the duodenum, was not to exceed 50 Gy. 
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Tegafur/ Uracil (UFT) was administered orally, three doses of 100 mg/m2 per day for 28 days 
concomitant with radiotherapy, combined with 30 mg of leucovorin (folinic acid) per dose UFT 
and celecoxib 400 mg twice a day.
Treatment was interrupted in case of ≥ grade III toxicity. Anti-emetics or anti-diarrheic medication 
was provided if necessary. Furthermore, an H2-receptor antagonist was offered during the first 6 
months to diminish prevent peptic ulcers. 
Outcome measures and statistical analysis
The primary endpoint was time to progression. Secondary endpoints were overall survival, 
response rate, toxicity and resectability rate following treatment. Eighty patients were included 
as stated in the protocol.
Analysis was performed with the Statistical Package for the Social Sciences version 15.0 (SPSS) 
using the Kaplan Meier method. Survival curves were compared with the log-rank test. All 
analyses were performed on an intention-to-treat basis. 
RESULTS
Patients
From August 2003 until March 2007 109 consecutive patients with locally advanced pancreatic 
cancer presented in the Academic Medical Centre, Amsterdam or the Erasmus Medical Centre, 
Rotterdam. Of these 109 patients, 83 patients were included in this prospective phase II study. 
Twenty six patients were not included because they did not want to participate in the study (n=8), 
had metastatic disease at laparoscopy/laparotomy (n=7), had a performance of WHO>2 (n=6), 
pancreatic malignancy was not proven (n=2), had a previous bladder carcinoma (n=1), were 
hypersensitive for celecoxib (n=1) or had too high levels of bilirubin (n=1)  
Patient characteristics are listed in Table 1. The median tumour size (largest diameter) was 
40mm(range 24 - 70mm). The majority of the tumours were localised in the pancreatic head (83%). 
Enlarged peripancreatic lymph nodes were present in 53%of the patients and unresectability 
was mainly caused by vascular involvement (81%). Forty five patients underwent surgery before 
inclusion and bypasses were performed in 76% (n = 34) of these patients.
Median time from informed consent to start of treatment was 29 days (7-55) 
Four patients (5%) were lost to follow up during or shortly after treatment. These patients all 
died, and the date, but not the cause of death was retrieved. Four patients were still alive at the 
time of the last analysis. Median follow up for these four patients was 28 months (range 16 - 43). 
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Table 1. Baseline Characteristics of Eligible Patients:
N= 83
Hospital; number (%)
    Academic Medical Centre
    Erasmus Medical Centre
61 (74)
22 (27)
Mean age; yr (range) 62 (39-79)
Sex; number (%)
    Male
    Female
42 (51)
41 (49)
Median tumour size; mm (range) 40 (24 -70)
Enlarged peripancreatic lymph nodes;
number (%) 44 (53)
Cause of unresectability; number (%)
    Vascular involvement
    Lympnodes outside the resection field  
    Combination of above
    Ingrowth into surrounding tissue
67 (84)
4 (5)
8 (10)
4 (5)
Compliance and adverse effects 
In total, 46 patients (55%) received the entire treatment schedule as planned in the protocol. 
Eight patients (10%) interrupted therapy for 1 - 3 days due to gastro-intestinal toxicity (n = 4), a 
skin rash (n = 2), leucopenia (n = 1) or problems with oral UFT intake (n = 1). Two patients had 
to stop celecoxib after 11 and 14 days due to a skin rash but continued the chemoradiotherapy. 
Twenty six patients had to stop treatment due to gastro-intestinal toxicity (n = 22; 27%) with 
(n = 3; 4%) or without haematological toxicity, skin rash (n = 3; 4%) or pneumonia (n = 1; 1%). 
The first included patient never started UFT, because it was not yet available (n = 1; 1%). Despite 
toxicity, 65 patients (78%) received the planned dose (50 Gray) of radiotherapy. Eighty per cent 
of the patients (n=66) received at least 3 weeks of therapy. Of the 27 patients who stopped 
treatment, three patients did so during the first week of therapy, three during the second week, 
eleven during the third week and ten during the fourth week. 
Overall grade III and IV and (early) grade V toxicity is shown in Table 2. Twenty-five patients 
(30%) were admitted into the hospital during or after treatment due to gastro-intestinal toxicity 
(n=20) or cholangitis (n=4). One patient developed an irreversible renal failure due to (biliary) 
sepsis (without leucopenia) and died the day of admission. Another patient was admitted to the 
hospital with dehydration and a severe decline in physical condition without disease progression, 
caused by nausea and vomiting CTC grade III, was rehydrated and treated with anti-emetics but 
died shortly thereafter. 
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Table 2. Toxicity
Grade III-IV
Number (%)
Haematological
Leucocytes 2 (2)
Potassium 1 (1)
Non-haematological
Anorexia 6 (7)
Nausea 11 (13)
Vomiting 8 (10)
Mucositis 3 (4)
Diarrhoea 9 (11)
Pain 4 (5)
Fever 1 (1)
Fatigue 4 (5)
Treatment efficacy
Response could be assessed in 79 patients. None of the patients had a partial or complete 
response and none underwent further exploratory surgery. Progression of disease occurred in 67 
patients (81%). Median time to progression in all 83 patients was 6.9 months (Figure 1). Forty 
two patients (51%) developed local progression, 25 patients (30%) developed distant progression 
and 21 (25%) patients developed both local and distant metastases simultaneously, Nine patients 
received further treatment consisting of gemcitabine (n=8) or radiotherapy (n=1).
Overall survival was based on 79 deaths. Cancer-related death accounted for 77% of the deaths 
(n = 61). In 7 patients (including the four lost to follow-up) the cause of death was unknown. 
Other causes of death were (biliary) sepsis (n  =  4), pneumonia (n  =  1), renal failure during 
treatment (n = 1), duodenal perforation due to stent (n = 1), haematemesis (n = 1), epileptic 
insults leading to coma (n = 1) and dehydration and diminished general condition caused by 
nausea and vomiting without tumour progression (n = 2), one during treatment. All but two of 
these non cancer-related deaths occurred more than two months after study treatment. 
Median overall survival in all patients was 10.6 months (Figure 1). Single log-rank tests showed 
that survival was similar in both hospitals (10.5 vs. 10.8 months; p=0.983), was independent 
of the performance of explorative surgery before the start of treatment, the localisation of the 
tumour (head vs. elsewhere), tumour size (≤ 40mm vs. > 40mm) or the presence of enlarged 
peripancreatic lymph nodes or vascular involvement. Furthermore, survival was not determined 
by the number of treatment weeks (≤ 3 vs. > 3 nor full treatment vs. partial treatment). 
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Prog. free      83               19                 5       2 1
Survival 83     47      10       4 2
At risk
Overall Survival
- - Progression free Survival
Fig. 1. Actuarial overall survival and progression free survival of all 83 patients.
DISCUSSION
In this multicentre phase-II trial the median overall survival was 10.6 months with a median time 
to progression of 6.9 months after oral Tegafur/ Uracil (UFT) combined with leucovorin (folinic 
acid), celecoxib and radiotherapy in patients with unresectable pancreatic cancer. Nineteen per 
cent of the patients did not progress during follow-up. None of the patients had a complete 
or partial response and none of the patients underwent an exploratory laparotomy to re-asses 
resectability. 
Toxicity was substantial: Two patients died during therapy, CTC grade III-IV toxicity occurred in 
23 patients (28%), and 80% (n = 66) of the patients had CTC grade ≥ II. However, compared 
to other studies with similar regimens in both pancreatic and rectal cancer21, 22, grade III-IV 
toxicity occurred in equivalent frequency. The high fraction doses of radiotherapy combined with 
celecoxib in such short interval may have accounted partly to the toxicity.
The survival of our patient group is poor and is in line with median survival after 5-fluorouracil 
(5-FU) based chemoradiotherapy treatment in literature (7- 14 months).9-11, 23-28 After treatment 
with gemcitabine either with or without concurrent radiotherapy, median survival varies between 
10- 17 months.23, 26-32 
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A recent randomised controlled trial performed by Chauffert23 revealed a significant survival 
benefit of gemcitabine alone, over intensive 5-FU and cisplatin based chemoradiotherapy 
followed by the same maintenance gemcitabine therapy (median survival 13 vs. 8.6 months; p= 
0.03). Based on this study, one could question whether radiotherapy should remain part of the 
treatment at all. However, this was an analysis of an unplanned interim analysis with only 42% of 
the patients receiving at least 75% of the protocol. Furthermore, no other study could reproduce 
the high survival in the gemcitabine arm.
More than half of the recurrences/progressions of pancreatic cancer occur locally, and cause 
severe pain in a high proportion of patients. Chemoradiotherapy has a potent effect on this 
pain.10, 33 Hence we believe that the search for better chemoradiotherapy remains valid. Probably 
chemoradiotherapy should be gemcitabine-based and combined with other new drugs with 
radio-, and/or chemo-enhancing potency.
In conclusion, based on the lack of response, the accompanying toxicity of mainly gastro-intestinal 
origin and the reported mediocre overall and progression free survival, we can not advise our 
short intensive chemoradiotherapy schedule consisting of radiation, 50 Gy in four weeks, oral 
UFT, leucovorin, and celecoxib as standard treatment in patients with locally advanced pancreatic 
cancer.
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ABSTRACT
Background: Radiotherapy is an established treatment for malignant localized disease. Pancreatic 
cancer however seems relatively insensitive to this form of therapy.
Methods: Pancreatic cancer cell lines MiaPaca-2 and Panc-1 were pre-treated with 3000 IU/ml 
IFNa or 100 IU/ml IFNb followed by 0, 2, 4 or 6 Gray (Gy) irradiation. Colony forming assay was 
used to assess the effects on cellgrowth. To measure the surviving fraction at the clinically relevant 
dose of 2 Gy (SF2), cells were pre-treated with 1000- 10.000 IU/ml IFNa or 50-500 IU/ml IFNb 
followed by 2 Gy irradiation.
Results: The plating efficiency was 49% for MiaPaca-2 and 22% for Panc-1. MiaPaca-2 was more 
radiosensitive than Panc-1 (surviving fraction of 0.28 vs. 0.50 at 4 Gray). The SF2 of MiaPaca-2 
was 0.77 while the SF2 of Panc-1 was 0.70. The SF2 significantly decreased after pretreatment 
with IFNa 1000 IU/ml (p<0.001) and IFNb 100 IU/ml (p<0.001) in MiaPaca-2 and with IFNa 5000 
IU/ml (p<0.001) and IFNb 100 IU/ml (p<0.01) in Panc-1. The sensitizing enhancement ratio (SER) 
for IFNa 3000 IU/ml was 2.15 in MiaPaca-2 and 1.90 in Panc-1. For IFNb 100 IU/ml the SER was 
1.72 for in MiaPaca-2 and 1.51 in Panc-1.
Conclusions: Type I interferons have radiosensitizing effects in pancreatic cancer cell lines. This 
radiosensitising property might lead to an improved response to treatment in pancreatic cancer. 
Interferon b is the most promising drug due to its effect in clinically obtainable doses.
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INTRODUCTION
Radiotherapy is an important treatment in cancer, especially for patients with advanced localized 
disease, with proven efficacy in many tumours.1-5 Based on several randomised controlled trials 
studying the effect of adjuvant (chemo)radiotherapy, pancreatic and periampullary cancers are 
fairly radiotherapy resistant.6-10
Often chemotherapeutics (5-fluorouracil (5-FU), gemcitabine) are used as radiosensitizers. Besides 
their direct cytotoxic effects caused by incorporation of the drugs as modified nucleotides into 
the DNA, even low doses of these drugs can be effective in radiosensitisation. Interference with 
normal repair of radiation-induced DNA damage with an inappropriate progression through S 
phase is key in their radiosensitizing properties causing late, unmanageable toxicities. A favourable 
side effect of their direct cytotoxicity is a relative increase in oxygenation, leading to an increased 
vulnerability for radiotherapy.11, 12 However, as mentioned, results of chemoradiotherapy are 
disappointing in pancreatic cancer.6-10 
In several tumours radiosensitizing properties of interferon alpha (IFNa) and interferon beta (IFNb) 
have been demonstrated in vitro13-17 as well as in vivo.18, 19 In pancreatic cancer cell lines, IFNa has 
already shown to act as radiosensitizer20 and in vivo promising therapy results have been reported 
combining 5-FU, cisplatinum, and radiation therapy with IFNa alone (5-year survival rate of 55%) 
or followed by 2 cycles of gemcitabine (median survival 25 months) in patients with resected 
pancreatic adenocarcinoma.21, 22 These results are currently reinvestigated in the phase III CapRI 
study.23
Type I interferons such as IFNa and IFNb, sort their effect through the same interferon receptor 
(IFNAR) with IFNb having a higher affinity. In vivo studies showed that approximately 20% of 
pancreatic cancers express IFNARs and that expression of the interferon receptor correlates with 
a significant survival benefit in patients with resected pancreatic cancer.24
The exact mechanism by which type I interferons cause radiosensitisation is unclear. Possibly, 
concomitant treatment with IFNs causes an inappropriate progression of cells into S-phase, 
thereby interfering with repair of radiation-induced damage or increasing the proportion of lethal 
to sublethal damage.17, 25
In this study we aim to gain insight in the radiosensitizing abilities of type I interferons, especially 
IFNb, in pancreatic cell lines. We decided to address these issues in colony forming assays, 
because besides the apoptotic effects of radiation and IFNs, the reproductive integrity of tumour 
cells (i.e. the capacity to produce an expanding colony of descendants, and therefore to regrow 
the tumour if left intact at the end of treatment) is of pivotal importance. 
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MATERIALS AND METHODS
Cell lines and culture conditions
The human pancreatic cell lines MiaPaCa-2 and Panc-1 were purchased from the American Type 
Culture Collection. The cells were cultured in a humidified incubator containing 5% CO2 at 37°C. 
MiaPaca-2 was cultured in RPMI 1640 and Panc-1 in DMEM both supplemented with 10% FCS, 
penicillin (1x105 U/l), fungizone (0.5 mg/l) and L-glutamine (2 mmol/l). Periodically, the cells were 
tested for Mycoplasma contamination, which was not detected. Cells were harvested with trypsin 
(0.05%), EDTA (0.02%) and resuspended in medium. Before plating, the cells were counted 
microscopically using a standard haemocytometer. Tryphan Blue staining was used to assess cell 
viability, which always exceeded 95%. Media and supplements were obtained from GIBCO Bio-
cult Europe (Invitrogen, Breda, The Netherlands). 
Drugs and Reagents 
Human recombinant IFN-a-2b (Intron-A) was obtained from Schering-Plough Corporation 
(Utrecht, The Netherlands), while human recombinant IFN-b-1a (Rebif) was acquired from Serono 
Benelux BV (Den Haag, The Netherlands). All compounds were stored at -20°C, and the stock 
solution was constituted in distilled water according to the manufacturer instructions. Doses of 
1000- 10.000 IU/ml for IFNa and 50- 500 IU/ml for IFNb were used.
Irradiation
Cells were exposed to gamma radiation from a 137Cs source at 70.9 cGy/min at room temperature 
under aerobic conditions. For radiation survival studies, cells were irradiated with 0, 2, 4, 6, 8 or 
10 Gray. In the combined modality treatment, the IFN treatment was given before irradiation for 
72 hours. Cells were irradiated with 0, 2, 4 or 6 Gray in the presence of the drug. 
Colony forming assay
Cells were plated onto poly-L-lysine coated, 60 mm Petri-dishes (6-12 cells/cm2) and cultured 
in complete medium for two weeks. Poly-L-lysine (10 mg/ml; Sigma-Aldrich, Zwijndrecht, The 
Netherlands) inhibited cells from dispersing from the growing colonies. 
Dose response curves for IFNa, IFNb and irradiation were established for both cell lines using a 
colony-forming assay. Therefore, seeded cells were allowed to attach for 24 hr prior to treatment 
with 1000- 10.000 IU/ml IFNa, 50- 500 IU/ml IFNb or 0- 10 Gray irradiation. Cell lines were treated 
with IFNs continuously and medium plus agents was replaced every three or four days. Fourteen 
days after seeding, colonies were fixed with 100% ethanol and stained with hematoxicilline to 
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allow calculation of their average colony-forming efficiency. Colonies containing >50 cells were 
counted automatically with the MultiImage Light Cabinet from HpH Innitech Corporation. 
Plating efficiency was defined as the mean number of colonies divided by the number of inoculated 
cells for control cultures not exposed to interferons or radiation. The surviving fraction (SF) was 
calculated as (mean number of colonies)/ (number of inoculated cells × plating efficiency). The 
curve was plotted using X-Y log scatter (Graph Prism 3.0). Curve-fitting parameters a and b were 
determined. 
Radiation enhancement by type I interferons
To asses radiation enhancement by type I interferons, cells were pretreated with IFNa 3000 IU/ml 
or IFNb 100 IU/ml (doses resulting in approximately 50% decrease in surviving fraction in both cell 
lines) for 72 hours. Cell lines were irradiated with 0, 2, 4 or 6 Gray. Control plates without IFNs 
were irradiated simultaneously. Cell lines were treated with IFNs continuously and medium plus 
agents was replaced every three or four days. After two weeks, the formed colonies were fixed 
and stained to allow counting.
SF2 is the surviving fraction of cells that were irradiated at the clinically relevant dose of 2 Gray.
The sensitizing enhancement ratio (SER) for interferon was calculated at the 37% survival level. 
The radiation dose that reduced the surviving colonies to 37% of the non-treated controls was 
divided by the radiation dose that reduced survival to 37% after interferon pre-treatment.
Cell proliferation assay 
Measurement of total DNA contents, representative for the number of cells, was performed 
using the bisbenzimide fluorescent dye (Hoechst TM 33258, Boehring Diagnostics, La Jolla, CA) as 
previously described.26
Measurement of DNA fragmentation (apoptosis)
10.000 cells/dish, depending on the length of the incubation period, were plated on 24-well 
plates and the cells were allowed to adhere overnight. The next day the cell culture medium 
was replaced with 1ml/well medium containing 3000 IU/ ml IFN-a or 100 IU/ml IFN-b. Each 
treatment was performed in quadruplicate. After an additional incubation of 3 days, apoptosis 
was assessed using a commercially available ELISA kit (Cell Death Detection ELISAPlus, Roche 
Diagnostic GmbH, Penzberg, Germany). The standard protocol supplied by the manufacturer was 
used. Relative apoptosis was determined by calculating the ratio of the average absorbance of 
the treatment dishes to the average absorbance of the control dishes. The data were corrected for 
the effect on cell number after 3 days of treatment. Intra- and interassay coefficients of variation 
were 4.2% and 6.3% respectively. 
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Statistical analyses
All experiments were carried out in duplicates and gave comparable results. For statistical analysis 
GraphPad PrismTM 3.0 (GraphPad Software, San Diego, USA) was used. The comparative 
statistical evaluation among groups was firstly performed by the ANOVA test. When significant 
differences were found, a comparison between groups was made using the Newman-Keuls test. 
The unpaired Student t-test was used to analyze the differences in surviving fraction for each 
dose point.
In all analyses, values of p<0.05 were considered statistically significant. Data are reported as 
mean + SEM. Statistical analysis was made after logarithmic transformation.
RESULTS
In vitro, the control plating efficiency (mean ± SD) was measured and amounted to 49 ± 3% for 
MiaPaca-2 and 22 ± 3% for Panc-1. 
Effect of type I interferons on relative clonogenic survival
Both IFNa and IFNb inhibited colony formation for both MiaPaca-2 and Panc-1 cells in a dose 
dependent manner (Figure 1). For all doses analysed, MiaPaca-2 was significantly more vulnerable 
to both IFNa and IFNb than Panc-1.
Besides inhibiting colony formation, type I interferon had growth inhibitory effects on both cell 
lines; after interferon treatment, colonies were significantly smaller than colonies from untreated 
cells (Figure 1). This finding is consistent with Vitale’s manuscript (27) demonstrating both growth 
inhibitory as well as pro-apoptotic properties of type I interferons with IFNb being the more 
potent pro-apoptotic drug than IFNa, where apoptosis only occurs in higher doses. 
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Figure 1 Effect of IFNa and IFNb treatment on colony forming ability in MiaPaca-2 (A,B) and 
Panc-1 (C,D). Pancreatic cancer cells were treated with IFNa (A,C) or IFNb (B,D) during 
fourteen days and both number and size of colonies were counted automatically. Data 
are the mean ± SEM. *=p<0.05 vs. control.
Effect of radiation on relative clonogenic survival
MiaPaca-2 was more radiosensitive than Panc-1 for 4, 6 and 8 Gray (Figure 2a). The surviving 
fraction at 2 Gy (SF2) of MiaPaca-2 was 0.77 while the SF2 of Panc-1 was 0.70. At 4 Gy however, 
the SF was 0.28 for MiaPaca-2 and 0.50 for Panc-1. The size of the colonies was not considerably 
influenced by radiotherapy (Figure 2b).
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Figure 2 Effect of irradiation on colony forming ability in MiaPaca-2 and Panc-1. Pancreatic cancer 
cells were treated with irradiation during fourteen days and both number and size of 
colonies were counted automatically. Data are the mean ± SEM. *=p<0.05 vs. control.
Effect of type I Interferons on apoptosis
Significant apoptosis corrected for DNA content occurred after 72 hours (Figure 3). Apoptosis 
increased to 802 ± 219% for IFNa 3000 IU/ml and 575 ± 119% for IFNb 100 IU/ml. In Panc-1 
apoptosis after 72 hours was 154 ± 14% for IFNa 3000 IU/ml and 139 ± 7% for IFNb 100 IU/ml.
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Figure 3 Effect of 3000 IU/ml IFNa and 100 IU/ml IFNb treatment on apoptosis (DNA fragmentation) 
in MiaPaCa-2 and Panc-1 cell lines. Cells were incubated for 3 days without (control) or 
with the drugs indicated. Values are absorbance units and are expressed as percent of 
the control. Data are the mean ± SEM. *=p<0.05 vs. control.
Surviving fraction at 2 Gray (SF2)
The SF2 of MiaPaca-2 was 0.77 while the SF2 of Panc-1 was 0.70. Pre-incubation with IFNa for 
72 hours at doses of 1000, 2000 or 5000 IU/ml changed the SF2 in MiaPaca-2 to 0.56, 0.47 and 
0.18 respectively. In Panc-1 pre-incubation with IFNa at doses of 2000, 5000 or 10.000 IU/ml 
changed the SF2 to 0.66, 0.22 and 0.18 respectively.
Pre-incubation with IFNb for 72 hours at doses of 50, 100 or 200 IU/ml changed the SF2 in 
MiaPaca-2 to 0.70, 0.33 and 0.22 respectively. In Panc-1 pre-incubation with IFNb at doses of 
100, 200 or 500 IU/ml changed the SF2 to 0.48, 0.24 and 0.23 respectively.
The decrease of SF2 compared to the SF2 without pre-incubation was significant after IFNa 2000 
IU/ml (p<0.01) and IFNa 5000 IU/ml (p<0.001) and IFNb 100 IU/ml and IFNb 200 IU/ml (p<0.001) 
in MiaPaca-2. In Panc-1 concentrations of IFNa 2000 IU/ml (p<0.01), IFNa 5000 IU/ml (p<0.001) 
and IFNa 10.000 IU/ml (p<0.001) and IFNb 100 IU/ml (p<0.001) IFNb 200 IU/ml (p<0.001) IFNb 
500 IU/ml (p<0.001) resulted in significant improved radiosensitivity (Figure 4).
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Figure 4 Effect of combined treatment with type I interferons and 2 Gy irradiation on colony 
forming ability in MiaPaCa-2 (A,B) and Panc-1 (C,D) cell lines. Cells were pretreated 
with IFNa (A,C) or IFNb (B,D) for 72 hours followed by irradiation with 2 Gy. The formed 
colonies were automatically counted after 2 weeks. Data are the mean ± SEM. *=p<0.05 
vs. control.
Effect of type I interferon on radiosensitivity
The radiotherapy dose required to reduce the surviving fraction to 37% was 3.98 Gy in MiaPaca-2 
for the non-treated controls. After IFNa 3000 IU/ml, the required dose was 1.85 Gy and after IFNb 
100 IU/ml, the required dose was 2.32 Gy. This leads to a sensitizing enhancement ratio (SER) of 
2.15 for IFNa 3000 IU/ml and a SER of 1.72 for IFNb 100 IU/ml in MiaPaca-2.
In Panc-1 the required radiotherapy dose to reduce the SF to 37% was 4.65 Gy for the non-
treated controls. After IFNa 3000 IU/ml, the required dose was 2.45 Gy and after IFNb 100 IU/
ml, the required dose was 3.07 Gy. This leads to a sensitizing enhancement ratio (SER) of 1.90 for 
IFNa 3000 IU/ml and a SER of 1.51 for IFNb 100 IU/ml in Panc-1.
The shape of the survival curves changed after treatment resulting in an increased steepness of the 
survival curve with an increase of the a-component after curve fitting (Figure 5). For MiaPaca-2 
this increase was significant for both IFNa as IFNb compared to the non-treated controls. In the 
Panc-1, we found no significant difference between the a-component after neither IFNa nor IFNb 
and the non-treated controls. In this cell line, after comparison of the radiosensitivity between 
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groups using the Newman-Keuls test, only the SF after 6 Gy of irradiation combined with IFNa or 
IFNb was significantly lower than after irradiation alone. All other SFs were similar after treatment 
or no treatment.
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Figure 5 Effect of combined treatment with 3000 IU/ml IFNa and 100 IU/ml IFNb and irradiation 
on colony forming ability in MiaPaCa-2 and Panc-1 cell lines. Cells were pretreated with 
IFNa or IFNb for 72 hours followed by 0, 2, 4 or 6 Gy irradiation. The formed colonies 
were automatically counted after 2 weeks. Data are the mean ± SEM. *=p<0.05 vs. 
control.
DISCUSSION
Our in vitro study shows a radiosensitizing effect of type I interferons on pancreatic cancer 
cell lines MiaPaca-2 and Panc-1. Miapaca-2 was 2.15 times more sensitive to radiotherapy 
after treatment with IFNa 3000 IU/ml and 1.72 times more sensitive after IFNb 100 IU/ml. The 
sensitivity to radiotherapy of Panc-1 increased 1.90 times after treatment with IFNa 3000 IU/ml 
and 1.51 times after IFNb 100 IU/ml. Radiosensitization was dose dependently, with higher doses 
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of interferons resulting in a higher radiosensitivity, i.e. a lower surviving fraction at 2 Gray (SF2). 
Both overall radiosensitivity and sensitivity to interferon therapy was higher in MiaPaca-2 than in 
Panc-1. Previously, IFN receptor expression (mRNA and protein) was shown by Vitale et al27, with 
MiaPaCa-2 expressing more plasma membrane located IFN receptors than Panc-1. Furthermore, 
treatment with type I interferons results in more apoptosis in MiaPaca-2 than in Panc-1, although 
only extremely high doses (>1000 IU/ml) of IFNa cause apoptosis.27
Tumours are most vulnerable for radiotherapy in case of adequate vascular supply (proper 
oxygenation) and appropriate cell cycling.11, 28 To enhance the effect of radiotherapy, effort has 
been made to find radiation sensitizers. Because hypoxic cells are known to be up to three-
fold more resistant to radiotherapy than well-oxygenated cells29, several strategies have been 
investigated to find ways to sensitize hypoxic cells to radiation. These strategies focus at reducing 
tumour hypoxia by increasing the delivery of oxygen to the tumour, administering oxygen mimetics 
and mimicking the effect of oxygen in the radiochemical process or by selective destruction of 
hypoxic cells, for instance by tirapazimine.30, 31 Trials show that reducing hypoxia by any means, 
leads to a better locoregional control and an improved survival, especially in head and neck 
cancer and cervical cancer.30
Resistance to apoptosis is the key factor for poor responses to therapies in pancreatic cancer. 
Ionising radiation alone causes a range of lesions in the DNA of target cells such as base damage, 
single-strand and double-strand breaks. Double-strand breaks are generally considered the lethal 
event but can be repaired by DNA repair mechanisms. Inadequately repaired DNA damage causes 
activation of the mitochondrial pathway of apoptosis by p53 resulting in activation of the caspase 
cascade. Membrane damage activates the stress-activated protein kinase pathway leading to 
activation of the mitochondrial pathway as well as a direct activation of caspases. Furthermore 
radiotherapy activates apoptosis due to stimulation of the death receptor pathway, consisting 
of the tumour necrosis factor (TNF) receptor superfamily (for instance TRAIL-R1 and TRAIL-R2). 
Activation causes direct activation of the caspase cascade. These cell death pathways are regulated 
by numerous signaling molecules, such as nuclear factor-kB (NF-kB), phosphatidylinositol 3-kinase 
(PI3K), inhibitor of apoptosis proteins (IAPs) and members of the Bcl-2 protein family.32, 33
Pancreatic cancer cells have developed multiple resistance mechanisms to therapy-induced 
apoptosis. The mitochondrial pathway of apoptosis is less activated due to inactivating p53 
mutations, present in >70% of the pancreatic cancers. If activated, this pathway has a diminished 
ability to activate the caspase cascade. Furthermore, pancreatic cancer cells overexpress anti-
apoptotic proteins, have inactivated pro-apoptotic genes and express decoy receptors to prevent 
activation of the death receptor pathway.34, 35
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In pancreatic cancer cell lines, IFNa has already shown to be able to avoid these resistance 
mechanisms and act as radiosensitizer.20 The exact mechanism by which IFN exerts this 
radiosensitising activity is unclear. Both IFNa and IFNb have direct anti-tumour effects including 
apoptosis, cell damage, upregulation of cancer antigens and a growth inhibitory effect with 
accumulation of cells in S phase. Indirect anti-tumour effects are caused by modulation of the 
immune system, mainly through activation of T-cells, macrophages and natural killer cells, and 
anti-angiogenesis activity by downregulation of the vascular endothelial growth factor (VEGF) 
receptor and an alteration in the expression of various oncogenes.27, 36-39 
In pancreatic cancer cell lines, type I interferons cause both direct apoptosis (at lower doses in IFNb) 
and radiosensitisation. The exact mechanism for enhancing radiosensitivity is unclear. Apparently 
the accumulation of cells in S phase caused by interferons, which is the most radioresistant part 
of the cell cycle, does not prevent radiosensitisation. A possible mechanism is the inability of cells 
to accumulate sublethal DNA damage with interferon interfering in the repair of this kind of DNA 
damage. Furthermore alteration in oncogene expression levels might sensitize radioresistant cells 
to radiotherapy. Because not only the pro-apoptotic effect of IFNs combined with radiotherapy 
but especially the reproductive capacity of the treated cells is related to treatment efficacy, we 
chose colony forming assays for our study.
Beneficial effects of IFNa combined with chemoradiotherapy were already demonstrated in phase 
II studies in patients with resectable pancreatic cancer.21, 22 However, treatment is associated with 
considerable toxicity21, 22, 40 and the optimal combination therapy considering efficacy as well as 
tolerability is yet to be determined.
In conclusion, our in vitro study shows that both IFNa and IFNb have radiosensitizing effects in 
pancreatic cancer cell lines that are not based on immunomodulatory properties. Radiosensitizing 
effects are dose dependent, and lower doses of IFNb than IFNa cause similar radiosensitisation. 
The effect of interferon seems related to the receptor status. The radiosensitising property of type 
I interferons might lead to an improved response to treatment in pancreatic cancer with interferon 
b being the most promising drug. Therefore, further clinical trials involving combination therapy 
of type I IFNs and radiotherapy are promising.
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Outcome in patients with pancreatic and periampullary cancer is poor and a curative treatment 
strategy with more effective drugs and individualised treatment regimens have yet to be discovered. 
In resectable cancer, both neo-adjuvant and adjuvant schedules were suggested including solely 
systemic therapy or combined systemic and local therapy. Hardly any differentiation was made 
between periampullary and pancreatic head cancer. In locally advanced cancer, patients with 
metastasised cancer were included in the same studies and based on these results, radiotherapy 
was declared ineffective. Over the years knowledge has evolved and studies have become more 
reproducible, but a breakthrough in patients’ survival was not found. 
PART I
RESECTABLE PANCREATIC AND PERIAMPULLARY CANCER
Patients with resectable pancreatic and periampullary cancer develop both local and distant 
metastases after resection. In order to prevent recurrent disease, a combined local and systemic 
adjuvant treatment should be considered. In part I we treated patients with intra-arterial 
chemotherapy. Celiac artery infusion (CAI), resulting in a higher dose delivered in the liver 
through the common hepatic artery, might extend survival in locally advanced nonresectable as 
well as in resected pancreatic cancers. This treatment reduced hepatic progression from 62% 
to 17% and hepatic metastases related death from 33% to 8%.1-3 However, no reduction in 
local recurrence rates was found in these studies and radiotherapy might be the solution for this 
problem. Therefore, we combined celiac artery infusion with radiotherapy (CAI/ RT). 
An important outcome of our studies is the significance of differentiating between periampullary 
tumours and pancreatic carcinoma. For the whole study group CAI/RT did not improve survival. 
Patients operated for periampullary tumours survived significantly longer compared to patients 
with pancreatic cancer (27 vs. 14 months; p<0.001) and developed less liver metastases after 
intra-arterial chemotherapy and radiotherapy compared to observation (log-rank p<0.03). 
Patients with pancreatic cancer developed more local recurrences compared to periampullary 
tumours (log-rank p<0.01) but CAI/RT had no significant effect on local recurrence rate (log-rank 
p=0.12) nor on the development of liver metastases compared to the observation group (log-rank 
p=0.76). Consequently, no effect of CAI/RT was found on overall survival in pancreatic cancer.
After long-term follow-up, these figures were in line with aforementioned. However, for the 
periampullary cancers the number of long-term survivors (>60 months) in the CAI/RT group was 
twofold the number of long-term survivors after surgery alone (5 vs. 10). This did not result in 
a long-term significant survival benefit (median actual survival of 37 vs. 28 months, p=0.08). 
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However, survival in patients with moderate/ poor differentiated periampullary cancers did benefit 
from CAI/RT (median 22 vs. 36 months, p<0.01 log-rank).
The overall survival in all patients (19 months after surgery combined with CAI/RT, 18 months 
after surgery alone) was lengthy compared to the median survival of 12-15 months after surgery 
alone described in literature.4, 5 However, evidently this was not caused by the treatment itself but 
might be the result of our high volume expertise and/ or the patient case mix (almost 50% of our 
patients had a periampullary tumour which favours survival).
Because this regime is quite intense, necessitating hospital admissions for every cycle and visits 
to the outpatient clinic daily during radiotherapy we concomitantly performed a quality of life 
investigation. According to the EORTC QLQ-C30 principles, CAI/ RT did not result in a worse 
quality of life compared to the observation arm and in some scores a positive effect was found. 
However, it is unclear if this effect was due to the placebo effect, to the provision of hope, or to 
the increased medical attention associated with being in a study (although follow up was similar 
for both groups) or due to minor tumour shrinkage relieving some of the symptoms and a longer 
disease free period.
In our opinion, differentiating between periampullary and pancreatic tumours is of paramount 
importance for further treatment strategies; Periampullary cancer has a more favourable survival 
pattern, suggesting another recurrence pattern and a different response to adjuvant treatment 
than pancreatic head cancer as found in our randomised controlled trial. This was also found in the 
ESPAC-3 trial were no effect of adjuvant chemotherapy was found in patients with periampullary 
cancer in contrast to patients with pancreatic cancer.6 Therefore, individualized treatment, for 
both periampullary tumours and pancreatic cancer is necessary. Since survival is substantially 
worse in patients with resectable pancreatic head tumours, neo-adjuvant treatment might be a 
better option, thereby selecting the better patients for resection. For patients with periampullary 
cancer, adjuvant CAI might be a novel option to reduce the development of liver metastasis, 
however local recurrence remains also in these patients a serious problem, which could not be 
prevented by radiotherapy. 
Since differentiating between pancreatic and periampullary cancer pre-operatively by CT 
scanning or endoscopic ultrasound appears to be difficult if not impossible, new treatment 
schedules including neoadjuvant therapy for only true pancreatic cancers will be difficult to 
develop. Nowadays the final diagnosis is based on histopathological findings of the operative 
specimen, thus requiring resection and consequently eliminating the possibility of tumour 
specific neoadjuvant treatment. And even pathological differentiation between periampullary 
(distal common bile duct, ampulla carcinomas) and the true pancreatic ductal adenocarcinomas 
is difficult although microRNA analysis might help differentiate.7 Due to their type-specific survival 
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patterns and different response to chemo(radio)therapy, differentiation should be made both for 
the patient (prognosis) as well as for research and further treatment options.
However future improvements in CT scanning techniques, endoscopic ultrasound experience with 
subsequent fine needle aspiration and DNA analysis might facilitate pre-operative differentiation 
and therefore facilitate individualised and targeted therapy. 
PART II
UNRESECTABLE PANCREATIC CANCER
Unresectable locally advanced pancreatic cancer should be differentiated from metastasised 
pancreatic cancer. In metastatic disease, the survival determining lesions occur outside the 
pancreas and it is an illusion to be able to treat this with localised (radio)therapy. 
Unresectability is based on (mainly arterial) vascular invasion. Resectability is assessed on CT scan 
by a dedicated radiologist. However, in our study laparoscopy nevertheless reveals CT occult 
metastases in 35% of the patients. A similar result was found by Shoup and Liu.8-10 Detection of 
these occult lesions might lead to amendment of the offered treatment in the individual patient, 
but might also explain negative study results of radiotherapy in these patients due to the actual 
metastasised character of their disease. A thoracic CT scan should be part of the work-up in these 
patients to exclude pulmonary metastases.
After ruling out metastasized disease, we treated this selected group of patient with true 
unresectable pancreatic cancer with oral Tegafur/ Uracil (UFT) combined with leucovorin (folinic 
acid), celecoxib and radiotherapy in a phase II trial. Unfortunately, toxicity was substantial 
and compared to literature, no clear survival benefit could be found of our short intensive 
chemoradiotherapy schedule consisting of radiation, 50 Gy in four weeks, oral UFT, leucovorin, 
and celecoxib (median overall survival was 10.6 months with a median time to progression of 
6.9 months) and none of the patients subsequently underwent an exploratory laparotomy.11-15 A 
recent randomised controlled trial performed by Chauffert16 revealed a significant survival benefit 
of gemcitabine alone, over intensive 5-FU and cisplatin based chemoradiotherapy followed by the 
same maintenance gemcitabine therapy (median survival 13 vs. 8.6 months; p= 0.03). 
Only after careful staging including laparoscopy, study results on either locoregional therapy or 
systemic therapy for locally advanced pancreatic cancer can be interpreted correctly. 
Chaufferts study is promising and the results should be confirmed. However, survival benefit is 
still only 4 months which leads the way for further research including newer agents. Based on 
our trial and recent literature, with promising results of the new FOLFIRINOX regimens, we will 
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initiate a phase II trial in patients with locally advanced pancreatic cancer. First, of all patients 
will be adequately staged, including diagnostic laparoscopy and will start with FOLFIRINOX. In 
case of stable disease or partial response, only these patients will start high dose stereotactic 
radiotherapy.
PART III
IN VITRO
Based on our studies, as well as on literature, pancreatic cancer is fairly radiotherapy-resistant. 
Because we believe in combined treatment aimed at either preventing local recurrence or tumour 
growth by radiotherapy and distant progression by chemotherapy, we sought for ways to enhance 
the effect of radiotherapy in pancreatic cancer. In several tumours radiosensitizing properties of 
interferon alpha (IFNa) and interferon beta (IFNb) have been demonstrated in vitro17-22 as well as 
in vivo.23, 24 In pancreatic cancer cell lines, IFNa has already shown to act as radiosensitizer.25 
The exact mechanism by which IFN exerts this radiosensitising activity is unclear. They have direct 
anti-tumour effects including apoptosis, cell damage, upregulation of cancer antigens and a 
growth inhibitory effect with accumulation of cells in S phase. The radiosensitising mechanism 
might result from the interference of interferon on the repair of sublethal DNA damage resulting 
in an inability of cells to accumulate this kind of DNA damage. Furthermore alteration in oncogene 
expression levels might sensitize radioresistant cells to radiotherapy.
In vivo studies showed that approximately 20% of pancreatic cancers express the universal IFN 
receptor (IFNAR) with a higher affinity for IFNb.26 We decided to address these issues in colony 
forming assays, because besides the apoptotic effects of radiation and IFNs, the reproductive 
integrity of tumour cells (i.e. the capacity to produce an expanding colony of descendants, and 
therefore to regrow the tumour if left intact at the end of treatment) is of pivotal importance. 
Our in vitro study shows a radiosensitizing effect of type I interferons on pancreatic cancer cell lines 
MiaPaca-2 and Panc-1. Miapaca-2 was 2.15 times more sensitive to radiotherapy after treatment 
with IFNa 3000 IU/ml and 1.72 times more sensitive after IFNb 100 IU/ml. The sensitivity to 
radiotherapy of Panc-1 increased 1.90 times after treatment with IFNa 3000 IU/ml and 1.51 times 
after IFNb 100 IU/ml. Radiosensitization was dose dependently, with higher doses of interferons 
resulting in a higher radiosensitivity, i.e. a lower surviving fraction at 2 Gray (SF2). Both overall 
radiosensitivity and sensitivity to interferon therapy was higher in MiaPaca-2 than in Panc-1, 
which does express more plasma membrane located IFN receptors than Panc-1. 
Beneficial effects of IFNa combined with chemoradiotherapy were already demonstrated in phase 
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II studies in patients with resectable pancreatic cancer. However, treatment is associated with 
considerable toxicity.27-29
Interferon b seems the most promising drug. One of the problems for future in vivo studies is 
obtaining a sufficient level of IFNb for a sufficient period in the cancerous pancreas without 
subsequent toxicity. 
Off course, interferons are not the only radiosensitising agencies. Newer drugs and newer 
combinations are under research all to improve survival in this still devastating disease. 
Pancreatic cancer, and to a lesser extend periampullary cancer, is such a devastating disease, only 
modestly repliant to regular treatment. A modestly positive effect of treatment in clinical studies 
only occurs in selected patients such as non-metastatic periampullary tumours and IFN receptor 
positive cells in the in vitro experiments. 
Already at diagnosis, we should be able to direct patients to their tumour specific treatment, 
which might be neo-adjuvant therapy. In patients with locally advanced disease, a diagnostic 
laparoscopy should be performed for optimal staging. Since we cannot differentiate at diagnosis 
between pancreatic and periampullary cancer we will not be able to proceed into an individualised 
neo-adjuvant treatment. Until then, unnecessary toxicity and diminished quality of life without 
consequent survival benefit in some patients cannot be avoided. Probably, pre-operative FNA 
biopsies followed by tumor genetic profiling will determine which patients might benefit from 
either neo-adjuvant therapy or personalized systemic chemo(radio)therapy.
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Alvleesklierkanker is de acht meest voorkomende vorm van kanker in Europa, met zo’n 96.000 
nieuw gediagnosticeerde patiënten per jaar. Het is een agressieve vorm van kanker waarbij 
het incidentie cijfer nagenoeg gelijk is aan het jaarlijkse mortaliteitscijfer. De 5 jaars overleving 
voor de gehele groep ten tijde van de diagnose ligt rond de 5%, met een mediane overleving 
van 2-8 maanden. Bij diagnose wordt onderscheid gemaakt tussen patiënten met resectabele, 
irresectabele en gemetastaseerde tumoren. Slechts in 15-20% van de patiënten betreft het een 
operabele tumor op het moment van diagnose en alleen deze patiënten zijn mogelijk curatief 
te behandelen. Het merendeel van de patiënten presenteert zich met lokaal doorgegroeide 
(irresectabel) of uitgezaaide (gemetastaseerde) tumoren waarvoor resectie geen optie meer is. 
In deze groep van patiënten is curatie niet mogelijk en zal een eventuele behandeling verlenging 
van het leven beogen, waarbij de kwaliteit van leven voor deze patiënten van groot belang is.. 
Het spreekt voor zich dat patiënten na een succesvolle operatie een betere levensverwachting 
hebben dan patiënten met irresectabele of gemetastaseerde tumoren. 
In het pancreas (alvleesklier) komen verschillende maligne (kwaadaardige) tumoren voor welke 
verschillen in biologisch gedrag. Meest voorkomend is het ductaal adenocarcinoom uitgaand 
van de ductale cellen (bekleding van de afvoergang). Dit is ook de meest agressieve vorm van 
pancreaskanker met de kortste overleving (5 jaars overleving 5% to 25%, mediaan 12-15 
maanden). De tweede vorm van kanker in de pancreaskop is het periampullair carcinoom. Deze 
tumoren zijn gelegen rond de uitmonding van de ductus pancreaticus en choledochus in het 
duodenum, de ampulla van Vater genaamd, en betreft zowel tumoren uitgaand van het laatste 
deel van de galgang, de ampul zelf of het duodenum. De overleving van deze patiënten na 
operatie is gunstiger dan voor patiënten met een ductaal adenocarcinoom (5 jaars overleving 
40% to 70%, mediaan 25- 42 maanden). 
RESECTABELE TUMOREN (DEEL I)
Ondanks dat de overleving van patiënten met resectabele pancreastumoren na resectie beter 
is dan voor patiënten met irresectabele of gemetastaseerde tumoren, is er met een mediane 
overleving van 12-15 maanden voldoende ruimte voor verbetering. De teleurstellende overleving 
wordt veroorzaakt door het ontstaan van lokale recidieven en metastasen (uitzaaiingen) bij 
90% van de patiënten. Juist om deze recidieven en metastasering terug te dringen is er in het 
verleden reeds gezocht naar een manier om naast lokale controle middels chirurgie in combinatie 
met radiotherapie, ook systemische controle middels aanvullende chemotherapie te verkrijgen. 
Verscheidene combinaties zijn in het verleden onderzocht, zonder eenduidig overlevingsvoordeel. 
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Een veelbelovende therapie is onderzocht in patiënten met resectabele en irresectabele tumoren 
waarbij chemotherapie gegeven wordt via een intra arteriële lijn gelegen in de truncus coeliacus 
(directe aflevering van de chemotherapie in de slagader naar de lever) waarbij een hoge dosis in 
de lever wordt bereikt. Dit heeft tot doel levermetastasen te voorkomen, maar heeft geen effect 
op het lokale recidief. Door radiotherapie aan dit schema toe te voegen, wat met name een lokaal 
effect heeft, wordt beoogd zowel lokaal als op afstand het recidief te voorkomen en daarmee 
de overleving na resectie in patiënten met ductaal adenocarcinoom en periampullaire tumoren 
te verlengen. 
De resultaten van een gerandomiseerde studie waarin deze aanvullende behandeling werd 
aangeboden aan patiënten na operatie worden beschreven in hoofdstuk 2. In de gecombineerde 
groep patiënten met ductaal adenocarcinoom of periampullaire tumor heeft deze intensieve vorm 
van nabehandeling geen effect op de overleving. In de gehele groep is er wel minder progressie 
van de ziekte, hetgeen met name bepaald wordt doordat de patiënten met periampullaire 
tumoren minder levermetastasen ontwikkelen. In deze selecte patiënten is er echter geen 
verlengde overleving, ook niet na lange termijn analyse (hoofdstuk 4). Het effect van deze 
langdurige en invasieve nabehandeling op de kwaliteit van leven is beschreven in hoofdstuk 
3 waarbij opvalt dat patiënten geen nadelige gevolgen ervaren op het gebied van lichamelijk, 
emotioneel en sociaal functioneren. Op het gebied van pijn, misselijkheid en braken werd zelfs 
een betere kwaliteit van leven vermeld over een periode van 24 maanden. 
IRRESECTABELE TUMOREN (DEEL II) 
Indien er geen sprake is van resectabele ziekte, is het van belang onderscheid te maken tussen 
lokale doorgroei (lokaal irresectabel) en gemetastaseerde (uitgezaaide) ziekte. Om te spreken van 
een lokaal irresectabel pancreascarcinoom, moeten metastasen uitgesloten worden. Hiertoe wordt 
in de dagelijkse praktijk een CT scan verricht en een röntgenfoto van de thorax (borstkas). Echter, 
in de literatuur is reeds bewezen dat kleine metastasen in de buikholte (peritoneaal metastasen) 
middels CT scan slecht gedetecteerd worden in patiënten met resectabele tumoren. Om een 
uniforme groep te creëren van patiënten met irresectabele, niet-gemetastaseerde ziekte, hebben 
we in hoofdstuk 5 bij alle patiënten met irresectabele tumoren een laparoscopie (kijkoperatie) 
uitgevoerd om peritoneaal metastasen uit te sluiten. In 35% van de patiënten werden alsnog 
peritoneaal metastasen aangetoond, hetgeen een verandering in het behandelschema teweeg 
bracht. 
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Vervolgens werden deze patiënten in een multicentrisch onderzoek in samenwerking met het 
Academisch Medisch Centrum, Amsterdam behandeld met radiotherapie, gecombineerd met 
middelen om het effect van de radiotherapie te versterken (1 chemotherapeuticum, foliumzuur 
en een ontstekingsremmer). Deze resultaten zijn beschreven in hoofdstuk 6. De mediane 
overleving na deze behandeling was 10.6 maanden en ernstige toxiciteit was aanwezig in 28% 
van de patiënten. Vergeleken met de overleving zonder behandeling (12- 15 maanden) wordt 
er geen overlevingswinst waargenomen en adviseren wij deze behandeling dus niet meer voor 
patiënten met een lokaal irresctabel pancreascarcinoom.
IN HET LAB (DEEL III)
Pancreascarcinoom blijkt vrij resistent tegen zowel chemo- als radiotherapeutische behandeling. 
Om de gevoeligheid voor radiotherapie te vergroten kunnen radiosensitizers toegevoegd worden 
aan de behandeling. Deze middelen zijn vooral van invloed op de celcyclus, met als doel om 
het merendeel van de cellen in dat deel van de cyclus te brengen dat het meest gevoelig is voor 
bestraling. 
Interferonen staan bekend om hun effect op de celcyclus en als radiosensitizers in andere 
tumorsoorten. Een deel van de pancreascarcinomen hebben interferon receptoren op hun 
membraan (buitenkant van de cel). Om deze reden, hebben we in verschillende pancreas 
cellijnen, met verschillende hoeveelheid interferonreceptoren op hun celmembraan, het effect 
van voorbehandeling met interferon op de gevoeligheid voor straling bepaald (hoofdstuk 7). 
Zowel interferon-a als interferon-b verhoogd het effect van radiotherapie, waarbij interferon-b 
met krachtigste effect. Dit zal in de toekomst vertaald moeten gaan worden naar een studie in 
patiënten. Bij voorkeur in die patienten waarbij bekend is dat er een grote hoeveelheid interferon 
receptoren op het celmembraan aanwezig is. 
Zoals beschreven in dit proefschrift, blijft het ductaal adenocarcinoom van het pancreas en in 
mindere mate ook de periampullaire tumoren, een levensbedreigende aandoening welke slechts 
matig respondeert op behandeling. 
Meer en meer zal gestreeft moeten worden naar een geindividualiseerde behandeling en verdient 
mogelijk voorbehandeling van deze tumoren de voorkeur. Echter zolang ten tijde van de diagnose 
geen onderscheid gemaakt kan worden tussen peri ampullaire en ductale pancreascarcinomen,is 
er nog een lange weg te gaan. Om de resultaten van nieuwe behandelingen juist te kunnen 
interpreteren is een zorgvuldige stagering van groot belang en dient dan ook bij patienten 
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met een lokaal irresectabele tumor een laparoscopie te worden uitgevoerd. Voor een betere 
individuele behandeling is mogelijk het nemen van preoperatieve biopten voor tumor genetic 
profiling een hoopvolle nieuwe ontwikkeling. 
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